ÌåäÓíèâåð - MedUniver.com Âñå ðàçäåëû ñàéòà Âèäåî ïî ìåäèöèíå Êíèãè ïî ìåäèöèíå Ôîðóì êîíñóëüòàöèé âðà÷åé  
Ðåêîìåíäóåì:
Ïåäèàòðèÿ:
Ïåäèàòðèÿ
Ãåíåòèêà â ïåäèàòðèè
Äåòñêàÿ àëëåðãîëîãèÿ è èììóíîëîãèÿ
Äåòñêàÿ ãàñòðîýíòåðîëîãèÿ
Äåòñêàÿ ãåìàòîëîãèÿ
Äåòñêàÿ ãèíåêîëîãèÿ
Äåòñêàÿ äåðìàòîëîãèÿ
Äåòñêàÿ è ïîäðîñòêîâàÿ ñòîìàòîëîãèÿ
Äåòñêàÿ êàðäèîëîãèÿ
Äåòñêàÿ íåâðîëîãèÿ
Äåòñêàÿ íåôðîëîãèÿ
Äåòñêàÿ îíêîëîãèÿ
Äåòñêàÿ îðòîïåäèÿ
Äåòñêàÿ îòîðèíîëàðèíãîëîãèÿ
Äåòñêàÿ îôòàëüìîëîãèÿ
Äåòñêàÿ ïóëüìîíîëîãèÿ
Äåòñêàÿ ðåàáèëèòàöèÿ
Äåòñêàÿ ðåâìàòîëîãèÿ
Äåòñêàÿ óðîëîãèÿ
Äåòñêàÿ ôàðìàêîëîãèÿ
Äåòñêàÿ ýíäîêðèíîëîãèÿ
Èíôåêöèîííûå áîëåçíè ó äåòåé
Íåîíàòîëîãèÿ
Íåîòëîæíûå ñîñòîÿíèÿ äåòåé
Ïîäðîñòêîâàÿ ìåäèöèíà
Ðîñò è ðàçâèòèå ðåáåíêà
Îðãàíèçàöèÿ ïåäèàòðè÷åñêîé ïîìîùè
Ôîðóì
 

Àâòîðû òðóäîâ (ñòàòåé) èñïîëüçîâàííûå ïðè ïîäãîòîâêå ìàòåðèàëîâ ïî äåòñêîé óðîëîãèè â ïåäèàòðèè

 ñòàòüÿõ íà ñàéòå èñïîëüçîâàíû ñëåäóþùèå ñîêðàùåíèÿ:

  • °F — òåìïåðàòóðà ïî Ôàðåíãåéòó
  • °C — òåìïåðàòóðà ïî Öåëüñèþ
  • 5-ÍÒ — 5-ãèäðîêñèèíäîëóêñóñíàÿ êèñëîòà ìî÷è
  • ÀÁ — àíòèáèîòèê(è)
  • ÀÁËÀ — àëëåðãè÷åñêèé áðîíõîëåãî÷íûé àñïåðãèëëåç
  • ÀÁÒ — àíòèáàêòåðèàëüíàÿ òåðàïèÿ
  • ÀÂ — àòðèîâåíòðèêóëÿðíûé
  • ÀÃ — àðòåðèàëüíàÿ ãèïåðòåíçèÿ
  • ÀÃí — àíòèãåí
  • ÀÄ — àðòåðèàëüíîå äàâëåíèå
  • ÀÄà — àíòèäèóðåòè÷åñêèé ãîðìîí
  • ÀÄÑ — àíàòîêñèí äèôòåðèéíî-ñòîëáíÿ÷íûé
  • ÀÄÑ-Ì — àíàòîêñèí äèôòåðèéíî-ñòîëáíÿ÷íûé (ìàëûå äîçû)
  • ÀÄÔ — àäåíîçèíäèôîñôîðíàÿ êèñëîòà, àäåíîçèíäèôîñôàò
  • ÀÊÄÑ — àíàòîêñèí êîêëþøíî-äèôòåðèéíî-ñòîëáíÿ÷íûé
  • ÀÊÒÃ — àäðåíîêîðòèêîòðîïíûé ãîðìîí
  • ÀÊØ — àîðòîêîðîíàðíîå øóíòèðîâàíèå
  • ÀËÒ — àëàíèíàìèíîòðàíñôåðàçà
  • àìåð. — àìåðèêàíñêèé
  • ÀÌÊ — àçîò ìî÷åâèíû êðîâè
  • ÀÌÔ — àäåíîçèíìîíîôîñôîðíàÿ êèñëîòà, àäåíîçèíìîíîôîñôàò
  • ÀÍÀ — àíòèíóêëåàðíûå àíòèòåëà
  • àíàò. — àíàòîìè÷åñêèé
  • àíãë. — àíãëèéñêèé
  • ÀÏÔ — àíãèîòåíçèí-ïðåâðàùàþùèé ôåðìåíò
  • ÀÐÂÒ — àíòèðåòðîâèðóñíàÿ òåðàïèÿ
  • ÀÐÏ — àêòèâíîñòü ðåíèíà â ïëàçìå êðîâè
  • ACT — àñïàðòàòàìèíîòðàíñôåðàçà
  • ÀÒë — àíòèòåëî
  • ÀÒÔ — àäåíîçèíòðèôîñôîðíàÿ êèñëîòà, àäåíîçèíòðèôîñôàò
  • ÀóÄ — àóòîñîìíî-äîìèíàíòíûé
  • ÀóÐ — àóòîñîìíî-ðåöåññèâíûé
  • ÀÔÏ — α-ôåòîïðîòåèí
  • ÀÔÑ — àíòèôîñôîëèïèäíûé ñèíäðîì
  • ÀÕÝ — àöåòèëõîëèíýñòåðàçà
  • ÀÖÕ — àöåòèëõîëèí
  • À×Ò — àêòèâèðîâàííîå ÷àñòè÷íîå òðîìáîïëàñòèíîâîå âðåìÿ
  • ÁÀ — áðîíõèàëüíàÿ àñòìà
  • ÁÀÄ — áèîëîãè÷åñêè àêòèâíàÿ äîáàâêà
  • ÁÀË — áðîíõîàëüâåîëÿðíûé ëàâàæ
  • ÁÀÐ — áèïîëÿðíîå àôôåêòèâíîå ðàññòðîéñòâî (I èëè II òèïà)
  • ÁÊÊ — áîëüøîé êðóã êðîâîîáðàùåíèÿ
  • ÁËÄ — áðîíõîëåãî÷íàÿ äèñïëàçèÿ
  • ÁËÍÏà — áëîêàäà ëåâîé íîæêè ïó÷êà Ãèñà
  • ÁÌÑÝ — áþðî ìåäèêî-ñîöèàëüíîé ýêñïåðòèçû
  • ÁÏ — áðþøíàÿ ïîëîñòü
  • ÁÏÍÏà — áëîêàäà ïðàâîé íîæêè ïó÷êà Ãèñà
  • ÁÐÌ — áàçîâûå ðåàíèìàöèîííûå ìåðîïðèÿòèÿ
  • ÁÐÍÑ — áûñòðî ðàçðåøèâøååñÿ íåîáúÿñíèìîå ñîáûòèå
  • ÁÖÆ — áàöèëëà Êàëüìåòòà-Ãåðåíà â ò.÷. — â òîì ÷èñëå
  • ÁÔÏ - áèîôèçè÷åñêèé ïðîôèëü ïëîäà
  • â. — âåê
  • â/ — âíóòðè... â ñëîæíîñîñòàâíûõ ñëîâàõ (íàïð. â/ñîñóäèñòûé, â/÷åðåïíîé è ò.ï.)
  • â/à — âíóòðèàðòåðèàëüíî
  • â/â — âíóòðèâåííî
  • â/ê — âíóòðèêîæíî
  • â/ì — âíóòðèìûøå÷íî
  • ââ. — âåêà
  • â-âî — âåùåñòâî
  • ÂÂÝ — âîåííî-âðà÷åáíàÿ ýêñïåðòèçà
  • ÂÃÄ — âíóòðèãëàçíîå äàâëåíèå
  • ÂÃ× — âèðóñ ãåðïåñà ÷åëîâåêà
  • ÂÄÏ — âåðõíèå äûõàòåëüíûå ïóòè
  • ÂÆÊ — âíóòðèæåëóäî÷êîâîå êðîâîèçëèÿíèå
  • ÂÇÊ — âîñïàëèòåëüíûå çàáîëåâàíèÿ êèøå÷íèêà
  • ÂÇÎÌÒ—âîñïàëèòåëüíûå çàáîëåâàíèÿ îðãàíîâ ìàëîãî òàçà
  • ÂÈÏ — âàçîàêòèâíûé èíòåñòèíàëüíûé ïåïòèä
  • ÂÈ× — âèðóñ èììóíîäåôèöèòà ÷åëîâåêà
  • ÂÌÏ — âûñîêîòåõíîëîãè÷íàÿ ìåäèöèíñêàÿ ïîìîùü
  • ÂÌÑ — âíóòðèìàòî÷íîå ñðåäñòâî (ñïèðàëü)
  • ÂÍ — âèðóñíàÿ íàãðóçêà
  • ÂÍÑ — âåãåòàòèâíàÿ íåðâíàÿ ñèñòåìà
  • ÂΠ— Âåëèêàÿ Îòå÷åñòâåííàÿ âîéíà
  • ÂÎÃÌ — âûñîêîãîðíûé îòåê ãîëîâíîãî ìîçãà
  • ÂÎÇ — Âñåìèðíàÿ îðãàíèçàöèÿ çäðàâîîõðàíåíèÿ
  • ÂÎË — âûñîêîãîðíûé îòåê ëåãêèõ
  • ÂÎÌÊ — âðà÷, îñóùåñòâëÿþùèé ìåäèöèíñêèé êîíòðîëü
  • ÂÎÏ — âðà÷ îáùåé ïðàêòèêè
  • ÂÏÂ — âåðõíÿÿ ïîëàÿ âåíà
  • ÂÏÃ — âèðóñ ïðîñòîãî ãåðïåñà
  • ÂÏÐ — âðîæäåííûå ïîðîêè ðàçâèòèÿ
  • ÂÏÑ — âðîæäåííûé ïîðîê ñåðäöà
  • ÂÏ× — âèðóñ ïàïèëëîìû ÷åëîâåêà
  • ÂÐÒ — âñïîìîãàòåëüíûå ðåïðîäóêòèâíûå òåõíîëîãèè
  • ÂÑÎ — âîäíî-ñîëåâîé îáìåí
  • Â×Ä — âíóòðè÷åðåïíîå äàâëåíèå
  • Â×ÈÂË — âûñîêî÷àñòîòíàÿ èñêóññòâåííàÿ âåíòèëÿöèÿ ëåãêèõ (HFV)
  • ÂÝÁ — âèðóñ Ýïøòåéíà-Áàðð
  • ã — ãðàìì
  • ã. — ãîä
  • Ã-6-ÔÄ — ãëþêîçî-6-ôîñôàòäåãèäðîãåíàçà
  • ÃÀÌÊ — ãàììà-àìèíîìàñëÿíàÿ êèñëîòà
  • ÃÁ — ãèïåðòîíè÷åñêàÿ áîëåçíü
  • ÃÁÍ — ãåìîëèòè÷åñêàÿ áîëåçíü íîâîðîæäåííîãî
  • ÃÁÎ — ãèïåðáàðè÷åñêàÿ îêñèãåíàöèÿ
  • ÃÇÒ — ãèïåð÷óâñòâèòåëüíîñòü çàìåäëåííîãî òèïà
  • ãèñò. — ãèñòîëîãè÷åñêèé
  • ÃÊ — ãðóäíàÿ êëåòêà
  • ÃÊÌÏ — ãèïåðòðîôè÷åñêàÿ êàðäèîìèîïàòèÿ
  • ÃÊÑ — ãëþêîêîðòèêîñòåðîèä(û)
  • ÃËÃ — ãåìîôàãîöèòàðíûé ëèìôîãèñòèîöèòîç
  • ÃËÏÑ — ãåìîððàãè÷åñêàÿ ëèõîðàäêà ñ ïî÷å÷íûì ñèíäðîìîì
  • ÃÌ — ãîëîâíîé ìîçã
  • ÃÌ-ÊÑÔ — ãðàíóëîöèòàðíî-ìàêðîôàãàëüíûé êîëîíèåñòèìóëèðóþùèé ôàêòîð
  • ÃÌÔ — ãóàíîçèíìîíîôîñôàò
  • ÃíÐà — ãîíàäîòðîïèí-ðèëèçèíã-ãîðìîí
  • ÃÍÒ — ãèïåð÷óâñòâèòåëüíîñòü íåìåäëåííîãî òèïà
  • ÃÏÎÄ — ãðûæà ïèùåâîäíîãî îòâåðñòèÿ äèàôðàãìû
  • ÃÐÄÑ — ãèïîêñè÷åñêàÿ ðåàêöèÿ äûõàòåëüíîé ñèñòåìû ãðå÷. — ãðå÷åñêèé
  • ÃÒÔ — ãóàíîçèíòðèôîñôàò
  • ÃÓÑ — ãåìîëèòèêî-óðåìè÷åñêèé ñèíäðîì
  • Ãö — ãåðö
  • ÃÝÁ — ãåìàòîýíöåôàëè÷åñêèé áàðüåð
  • ÃÝÐ — ãàñòðîýçîôàãåàëüíûé ðåôëþêñ
  • ÃÝÐÁ — ãàñòðîýçîôàãåàëüíàÿ ðåôëþêñíàÿ áîëåçíü
  • äÁ — äåöèáåë
  • ÄÂÑ — äèññåìèíèðîâàííîå âíóòðèñîñóäèñòîå ñâåðòûâàíèå
  • ÄÃÒ — äèãèäðîòåñòîñòåðîí
  • ÄÄ — äèôôåðåíöèàëüíàÿ äèàãíîñòèêà, äèôôåðåíöèàëüíî-äèàãíîñòè÷åñêèé
  • ÄÄÁÀ — äëèòåëüíîäåéñòâóþùèå β2-àãîíèñòû
  • ÄÄÊ — äèôôåðåíöèàëüíî-äèàãíîñòè÷åñêèé êðèòåðèé (êðèòåðèè)
  • ÄÄÐÌ - äîïóñòèìûé äèàïàçîí ðàñïðåäåëåíèÿ ìàêðîíóòðèåíòîâ
  • ÄÈ — äîâåðèòåëüíûé èíòåðâàë
  • ÄÊ — äèàãíîñòè÷åñêèé êðèòåðèé
  • ÄÊÀ — äèàáåòè÷åñêèé êåòîàöèäîç
  • ÄÊÌÏ — äèëàòàöèîííàÿ êàðäèîìèîïàòèÿ
  • ÄÌÆÏ — äåôåêò ìåææåëóäî÷êîâîé ïåðåãîðîäêè
  • ÄÌÏÏ — äåôåêò ìåæïðåäñåðäíîé ïåðåãîðîäêè
  • ÄÌÑ — äîáðîâîëüíîå ìåäèöèíñêîå ñòðàõîâàíèå
  • ÄÍ — äûõàòåëüíàÿ íåäîñòàòî÷íîñòü
  • ÄÍÊ — äåçîêñèðèáîíóêëåèíîâàÿ êèñëîòà
  • ÄÍÒ — äåôåêòû íåðâíîé òðóáêè
  • ÄÎ - äûõàòåëüíûé îáúåì
  • ÄÎÔÀ — äèãèäðîêñèôåíèëàëàíèí
  • ÄÏ — äûõàòåëüíûå ïóòè
  • ÄÏÊ — äâåíàäöàòèïåðñòíàÿ êèøêà
  • ÄÏÌ — äàòà ïîñëåäíåé ìåíñòðóàöèè
  • ÄÏÏ - äîïóñòèìûé ïðåäåë ïîòðåáëåíèÿ
  • äð. — äðóãèå
  • ÄÒÏ — äîðîæíî-òðàíñïîðòíîå ïðîèñøåñòâèå
  • ÄÖÏ — äåòñêèé öåðåáðàëüíûé ïàðàëè÷
  • ÅÄ — åäèíèöà äåéñòâèÿ, åäèíèöà
  • ÆÂÏ — æåë÷åâûâîäÿùèå ïóòè
  • ÆÄÀ — æåëåçîäåôèöèòíàÿ àíåìèÿ
  • ÆÅË — æèçíåííàÿ åìêîñòü ëåãêèõ
  • ÆÊÁ — æåë÷åêàìåííàÿ áîëåçíü
  • ÆÊÊ — æåëóäî÷íî-êèøå÷íîå êðîâîòå÷åíèå
  • ÆÊÒ — æåëóäî÷íî-êèøå÷íûé òðàêò
  • ÆÍÂËÏ — æèçíåííî íåîáõîäèìûå è âàæíûå ëåêàðñòâåííûå ïðåïàðàòû (ñïèñîê, ïåðå÷åíü)
  • ÇÂÓÐ — çàäåðæêà âíóòðèóòðîáíîãî ðàçâèòèÿ
  • ÇË — çäîðîâûå ëþäè (ëèöà)
  • ÇÍÎ — çëîêà÷åñòâåííîå íîâîîáðàçîâàíèå
  • ÇÎ — çäðàâîîõðàíåíèå
  • ÇÎÆ — çäîðîâûé îáðàç æèçíè
  • ÇÑÍ — çàñòîéíàÿ ñåðäå÷íàÿ íåäîñòàòî÷íîñòü
  • èÀÏÔ — èíãèáèòîðû àíãèîòåíçèí-ïðåâðàùàþùåãî ôåðìåíòà
  • ÈÁÑ — èøåìè÷åñêàÿ áîëåçíü ñåðäöà
  • ÈÂË — èñêóññòâåííàÿ âåíòèëÿöèÿ ëåãêèõ
  • ÈÃÊÑ — èíãàëÿöèîííûå ãëþêîêîðòèêîñòåðîèäû
  • ÈÇË — èíòåðñòèöèàëüíûå çàáîëåâàíèÿ ëåãêèõ
  • ÈÊÏ — èììóíîêîìïðîìåòèðîâàííûå ïàöèåíòû
  • ÈË — èíòåðëåéêèí
  • ÈËÄÁ — èíòåãðèðîâàííîå ëå÷åíèå äåòñêèõ áîëåçíåé
  • ÈÌ — èíôàðêò ìèîêàðäà
  • ÈÌÀÎ — èíãèáèòîð(û) ìîíîàìèíîêñèäàçû
  • ÈÌáïÁÒ — èíôàðêò ìèîêàðäà áåç ïîäúåìà ñåãìåíòà ST
  • ÈÌÏ — èíôåêöèÿ ìî÷åâûõ (ìî÷åâûâîäÿùèõ) ïóòåé
  • ÈÌïÇÒ — èíôàðêò ìèîêàðäà ñ ïîäúåìîì ñåãìåíòà
  • ST ÈÌÒ — èíäåêñ ìàññû òåëà
  • ÈÎË — èíòðàîêóëÿðíàÿ ëèíçà
  • ÈÏÏ — èíãèáèòîðû ïðîòîííîé ïîìïû (ïðîòîííîãî íàñîñà)
  • ÈÏÏÏ — èíôåêöèè, ïåðåäàâàåìûå ïîëîâûì ïóòåì
  • ÈÑÑ — èíäèâèäóàëüíûå ñïàñàòåëüíûå ñðåäñòâà èñòîð. — èñòîðè÷åñêîå èòàë. — èòàëüÿíñêèé
  • ÈÒÏ — èäèîïàòè÷åñêàÿ òðîìáîöèòîïåíè÷åñêàÿ ïóðïóðà
  • ÈÒØ — èíôåêöèîííî-òîêñè÷åñêèé øîê ÈÔÀ — èììóíîôåðìåíòíûé àíàëèç
  • ÊÀ — êîðîíàðíàÿ(ûå) àðòåðèÿ(è)
  • ê — êèëîâîëüò
  • êã — êèëîãðàìì
  • ÊÄÁÀ — êîðîòêîäåéñòâóþùèå β2-àãîíèñòû
  • ÊÄÄ — êîíå÷íî-äèàñòîëè÷åñêîå äàâëåíèå
  • ÊÄÎ — êîíå÷íî-äèàñòîëè÷åñêèé îáúåì
  • ÊÄÐ — êîíå÷íî-äèàñòîëè÷åñêèé ðàçìåð
  • êèò. — êèòàéñêèé
  • êêàë — êèëîêàëîðèÿ
  • êë. — êëåòêè, êëåòîê
  • ÊÌÏ — êà÷åñòâî ìåäèöèíñêîé ïîìîùè
  • ÊîÀ — êîýíçèì À, êîôåðìåíò À
  • ÊÎÅ — êîëîíèåîáðàçóþùàÿ åäèíèöà
  • ÊÎÊ — êîìáèíèðîâàííûå îðàëüíûå êîíòðàöåïòèâû
  • ÊÏÒ — êîãíèòèâíî-ïîâåäåí÷åñêàÿ òåðàïèÿ
  • ÊÐ — êëèíè÷åñêèå ðåêîìåíäàöèè
  • ÊÑÄ — êîíå÷íî-ñèñòîëè÷åñêîå äàâëåíèå
  • ÊÑÎ — êîíå÷íî-ñèñòîëè÷åñêèé îáúåì
  • ÊÑÐ — êîíå÷íî-ñèñòîëè÷åñêèé ðàçìåð
  • ÊÒ — êîìïüþòåðíàÿ òîìîãðàôèÿ
  • ÊÒÂÐ — êîìïüþòåðíàÿ òîìîãðàôèÿ âûñîêîãî ðàçðåøåíèÿ
  • ÊÒÃ — êàðäèîòîêîãðàôèÿ
  • ÊÔÊ — êðåàòèíôîñôîêèíàçà
  • ÊÙÑ — êèñëîòíî-ùåëî÷íîå ñîñòîÿíèå
  • ë — ëèòð
  • ë/î — ëîæíîîòðèöàòåëüíûé
  • ë/ï — ëîæíîïîëîæèòåëüíûé
  • ËÀ — ëåãî÷íàÿ àðòåðèÿ
  • ëàò. — ëàòèíñêèé
  • ËÃ — ëþòåèíèçèðóþùèé ãîðìîí
  • ËÄÃ — ëàêòàòäåãèäðîãåíàçà
  • ËÆ — ëåâûé æåëóäî÷åê
  • ËÎÐ — èìåþùèé îòíîøåíèå ê îòîðèíîëàðèíãîëîãèè (ËÎÐ-âðà÷, ËÎÐ-îðãàíû)
  • ËÏ — ëåêàðñòâåííûé ïðåïàðàò
  • ËÏÂÏ — ëèïîïðîòåèíû âûñîêîé ïëîòíîñòè
  • ËÏÍÏ — ëèïîïðîòåèíû íèçêîé ïëîòíîñòè
  • ËÏÎÍÏ — ëèïîïðîòåèíû î÷åíü íèçêîé ïëîòíîñòè
  • ËÏÓ — ëå÷åáíî-ïðîôèëàêòè÷åñêîå ó÷ðåæäåíèå
  • ËÑ — ëåêàðñòâåííîå ñðåäñòâî
  • ËÓ — ëèìôàòè÷åñêèé óçåë, ëèìôîóçëû
  • ËÔÊ — ëå÷åáíàÿ ôèçêóëüòóðà
  • ì.á. — ìîæåò (ìîã, ìîãóò, ìîãëè) áûòü
  • Ì/Æ — ñîîòíîøåíèå ìóæ÷èí è æåíùèí
  • ìàêñÄ — ìàêñèìàëüíàÿ äîçà
  • ìàêñÍÄ — ìàêñèìàëüíàÿ íà÷àëüíàÿ äîçà
  • ìàêñÐÄ — ìàêñèìàëüíàÿ ðàçîâàÿ äîçà
  • ìàêñÑÄ — ìàêñèìàëüíàÿ ñóòî÷íàÿ äîçà
  • ÌÀÍÊ — ìåòîä àìïëèôèêàöèè íóêëåèíîâûõ êèñëîò
  • ÌÀÎ — ìîíîàìèíîêñèäàçà
  • ÌÂÏ — ìî÷åâûâîäÿùèå ïóòè ìã — ìèëëèãðàìì
  • ÌÄÁ — ìûøå÷íàÿ äèñòðîôèÿ Áåêêåðà
  • ÌÄÄ — ìûøå÷íàÿ äèñòðîôèÿ Äþøåííà
  • ÌÄÌÀ — ìåòèëåíäèîêñèìåòàìôåòàìèí
  • ME — ìåæäóíàðîäíàÿ åäèíèöà
  • ìåä. — ìåäèöèíñêèé
  • ìåñ — ìåñÿö
  • ÌÆ — ìîëî÷íàÿ æåëåçà
  • ÌÆÏ — ìåææåëóäî÷êîâàÿ ïåðåãîðîäêà
  • ÌÇ — ìèíèñòåðñòâî çäðàâîîõðàíåíèÿ
  • ìèí — ìèíóò(à)
  • ìèíÄ — ìèíèìàëüíàÿ äîçà
  • ìèíÑÄ — ìèíèìàëüíàÿ ñóòî÷íàÿ äîçà
  • ÌÊÁ — ìî÷åêàìåííàÿ áîëåçíü
  • ÌÊÁ-10 — Ìåæäóíàðîäíàÿ êëàññèôèêàöèÿ áîëåçíåé 10-ãî ïåðåñìîòðà
  • ÌÊÁ-11 — Ìåæäóíàðîäíàÿ êëàññèôèêàöèÿ áîëåçíåé 11-ãî ïåðåñìîòðà
  • ìê — ìèêðîâîëüò
  • ìêã — ìèêðîãðàìì
  • ÌÊÊ — ìàëûé êðóã êðîâîîáðàùåíèÿ
  • ìêë — ìèêðîëèòð
  • ìë — ìèëëèëèòð
  • ìëí — ìèëëèîí
  • ìëðä — ìèëëèàðä
  • ìì — ìèëëèìåòð
  • ìì ðò.ñò. — ìèëëèìåòð ðòóòíîãî ñòîëáà ììîëü — ìèëëèìîëü
  • ÌÍÍ — ìåæäóíàðîäíîå íåïàòåíòîâàííîå íàèìåíîâàíèå
  • ÌÍÎ — ìåæäóíàðîäíîå íîðìàëèçîâàííîå îòíîøåíèå
  • ÌÎ — ìåäèöèíñêàÿ îðãàíèçàöèÿ
  • ÌÏ — ìåäèöèíñêàÿ ïîìîùü
  • ÌÏÑ — ìî÷åïîëîâàÿ ñèñòåìà
  • ÌÐ — ìàãíèòíî-ðåçîíàíñíûé
  • ÌÐ-âåíîãðàôèÿ — ÌÐÒ âåí è ñèíóñîâ ãîëîâíîãî ìîçãà
  • ÌÐÒ — ìàãíèòíî-ðåçîíàíñíàÿ òîìîãðàôèÿ
  • ìñ — ìèëëèñåêóíäà
  • ÌÑÊÒ — ìóëüòèñïèðàëüíàÿ êîìïüþòåðíàÿ òîìîãðàôèÿ
  • ÌÑÝ — ìåäèêî-ñîöèàëüíàÿ ýêñïåðòèçà
  • ÌÒ — ìàññà òåëà
  • ìòÄÍÊ — ìèòîõîíäðèàëüíàÿ äåçîêñèðèáîíóêëåèíîâàÿ êèñëîòà
  • ÌÒÐ — ìàññà òåëà ïðè ðîæäåíèè
  • ÌÝ - ìèàëãè÷åñêèé ýíöåôàëîìèåëèò
  • í.ý. — íàøåé ýðû
  • ÍÀ — íåðâíàÿ àíîðåêñèÿ
  • ÍÀÄ — íèêîòèíàìèäàäåíèíäèíóêëåîòèä
  • ÍÀÄÍ — íèêîòèíàìèäàäåíèíäèíóêëåîòèä (âîññòàíîâëåííûé)
  • ÍÀÄÔ — íèêîòèíàìèäàäåíèíäèíóêëåîòèäôîñôàò
  • ÍÀÆÁÏ — íåàëêîãîëüíàÿ æèðîâàÿ áîëåçíü ïå÷åíè íàïð. — íàïðèìåð
  • ÍÁ — íåðâíàÿ áóëèìèÿ
  • ÍÄÎ — íåãàòèâíûé äåòñêèé îïûò
  • íåä — íåäåëè
  • íåì. — íåìåöêèé
  • íì — íàíîìåòð
  • ÍÌÈÖ — íàöèîíàëüíûé ìåäèöèíñêèé èññëåäîâàòåëüñêèé öåíòð
  • ÍÌÏ — íåîòëîæíàÿ (ìåäèöèíñêàÿ) ïîìîùü
  • ÍÌÒ — íèçêàÿ ìàññà òåëà
  • ÍÏÀ — íîðìàòèâíî-ïðàâîâîé àêò
  • ÍÏÂ — íèæíÿÿ ïîëàÿ âåíà
  • ÍÏÂÑ — íåñòåðîèäíûå ïðîòèâîâîñïàëèòåëüíûå ñðåäñòâà
  • ÍÑ — íåðâíàÿ ñèñòåìà
  • ÍÑÒ - íåñòðåññîâûé òåñò
  • ÍÐÏ — íîðìû ðàöèîíà ïèòàíèÿ
  • ÍÑÃ — íåéðîñîíîãðàôèÿ
  • ÍÝÊ — íåêðîòè÷åñêèé ýíòåðîêîëèò
  • ÍßÊ — íåñïåöèôè÷åñêèé ÿçâåííûé êîëèò
  • ÎÀÊ — îáùèé àíàëèç êðîâè
  • ÎÀÌ — îáùèé àíàëèç ìî÷è
  • ÎÀÏ — îòêðûòûé àðòåðèàëüíûé ïðîòîê
  • ÎÁÏ — îðãàíû áðþøíîé ïîëîñòè
  • ÎÃÁ — îñòðàÿ ãîðíàÿ áîëåçíü
  • ÎÃÌ — îòåê ãîëîâíîãî ìîçãà
  • ÎÄÍ — îñòðàÿ äûõàòåëüíàÿ íåäîñòàòî÷íîñòü
  • ÎÆÑÑ — îáùàÿ æåëåçîñâÿçûâàþùàÿ ñïîñîáíîñòü ñûâîðîòêè
  • ÎÇ — îðãàíèçàöèÿ çäðàâîîõðàíåíèÿ
  • îê. — îêîëî
  • ÎÊÐ — îáñåññèâíî-êîìïóëüñèâíîå ðàññòðîéñòâî
  • ÎÊÑ — îñòðûé êîðîíàðíûé ñèíäðîì
  • ÎËË — îñòðûé ëèìôîáëàñòíûé ëåéêîç
  • ÎÌÑ — îáÿçàòåëüíîå ìåäèöèíñêîå ñòðàõîâàíèå
  • ÎÌÒ — îðãàíû ìàëîãî òàçà
  • ÎÍÌÊ — îñòðîå íàðóøåíèå ìîçãîâîãî êðîâîîáðàùåíèÿ
  • ÎÍÌÏ — îòäåëåíèå íåîòëîæíîé (ìåäèöèíñêîé) ïîìîùè
  • ÎÍÌÒ — î÷åíü íèçêàÿ ìàññà òåëà
  • ÎÎÇ — îðãàíû (îðãàíèçàöèè/óïðàâëåíèÿ) çäðàâîîõðàíåíèÿ
  • ÎÎÍ — Îðãàíèçàöèÿ Îáúåäèíåííûõ Íàöèé
  • ÎÏÆ — îæèäàåìàÿ ïðîäîëæèòåëüíîñòü æèçíè
  • ÎÏÍ — îñòðàÿ ïî÷å÷íàÿ íåäîñòàòî÷íîñòü
  • ÎÏÑÑ - îáùåå ïåðèôåðè÷åñêîå ñîñóäèñòîå ñîïðîòèâëåíèå
  • ÎÐÂÈ — îñòðàÿ ðåñïèðàòîðíàÿ âèðóñíàÿ èíôåêöèÿ
  • ÎÐÄÑ — îñòðûé ðåñïèðàòîðíûé äèñòðåññ-ñèíäðîì
  • ÎÐÇ — îñòðîå ðåñïèðàòîðíîå çàáîëåâàíèå
  • ÎÐÈÒ — îòäåëåíèå ðåàíèìàöèè è èíòåíñèâíîé òåðàïèè (ICU)
  • ÎÑÂÎ — îáùåå ñîäåðæàíèå âîäû â îðãàíèçìå
  • ÎÔÂ — îáúåì ôîðñèðîâàííîãî âûäîõà
  • ÎÔÂ1 — îáúåì ôîðñèðîâàííîãî âûäîõà çà 1-þ ñåêóíäó
  • ÎÖÊ — îáúåì öèðêóëèðóþùåé êðîâè
  • ï.ç. — ïîëå çðåíèÿ (ìèêðîñêîïà)
  • ï/ê — ïîäêîæíî
  • ÏÀÂ — ïñèõîàêòèâíûå âåùåñòâà
  • ÏÂ — ïðîòðîìáèíîâîå âðåìÿ
  • ÏÂÊ — ïåðèôåðè÷åñêèé âåíîçíûé êàòåòåð
  • ÏÂË — ïåðèâåíòðèêóëÿðíàÿ ëåéêîìàëÿöèÿ
  • Ïã — ïðîñòàãëàíäèí
  • ÏÃÃ — ïðîãðàììà ãîñóäàðñòâåííûõ ãàðàíòèé îêàçàíèÿ ãðàæäàíàì ÐÔ áåñïëàòíîé ìåäèöèíñêîé ïîìîùè
  • ÏÄÊÂ — ïîëîæèòåëüíîå äàâëåíèå êîíöà âûäîõà (PEEP)
  • ÏÆ — ïðàâûé æåëóäî÷åê
  • ÏÆÆ — ïîäæåëóäî÷íàÿ æåëåçà
  • ÏÆÊ — ïîäêîæíî-æèðîâàÿ êëåò÷àòêà (ãèïîäåðìà)
  • ÏÊÀ — ïî÷å÷íûé êàíàëüöåâûé àöèäîç
  • ÏÊÌÄ — ïîÿñíî-êîíå÷íîñòíàÿ ìûøå÷íàÿ äèñòðîôèÿ
  • ÏËÑÃ — ïÿòíèñòàÿ ëèõîðàäêà Ñêàëèñòûõ ãîð
  • ÏÌÄÐ — ïðåäìåíñòðóàëüíîå äèñôîðè÷åñêîå ðàññòðîéñòâî
  • ÏÌÊ — ïðîëàïñ ìèòðàëüíîãî êëàïàíà
  • ÏÌÑ — ïðåäìåíñòðóàëüíûé ñèíäðîì
  • ÏÌÑÏ — ïåðâè÷íàÿ ìåäèêî-ñàíèòàðíàÿ ïîìîùü
  • ÏÍÆÊ — ïîëèíåíàñûùåííûå æèðíûå êèñëîòû
  • ÏÎÐÈÒ— ïåäèàòðè÷åñêîå îòäåëåíèå ðåàíèìàöèè è èíòåíñèâíîé òåðàïèè
  • ÏÎÒ — ïîñòóðàëüíàÿ îðòîñòàòè÷åñêàÿ òàõèêàðäèÿ
  • ÏÏÂ — ïíåâìîêîêêîâàÿ ïîëèñàõàðèäíàÿ âàêöèíà
  • ÏÏÎÀÊ — ïðÿìûå ïåðîðàëüíûå àíòèêîàãóëÿíòû
  • ÏÏÒ — ïëîùàäü ïîâåðõíîñòè òåëà
  • ÏÑÀ — ïðîñòàòîñïåöèôè÷åñêèé àíòèãåí
  • ÏÑÂ — ïèêîâàÿ ñêîðîñòü âûäîõà
  • ÏÑÂÕ — ïðîãðåññèðóþùèé ñåìåéíûé âíóòðèïå÷åíî÷-íûé õîëåñòàç
  • ÏÒ — ïñèõîòåðàïèÿ
  • ÏÒÂ — ïðîòðîìáèíîâîå âðåìÿ
  • ÏÒÃ — ïàðàòèðåîèäíûé ãîðìîí
  • ÏÒÈ — ïðîòðîìáèíîâûé èíäåêñ
  • ÏÒÑÐ — ïîñòòðàâìàòè÷åñêîå ñòðåññîâîå ðàññòðîéñòâî
  • ÏÔÝ — ïèùåâîé ôîëàòíûé ýêâèâàëåíò
  • ÏÖÐ — ïîëèìåðàçíàÿ öåïíàÿ ðåàêöèÿ
  • ÏØÃ — ïóðïóðà Øåíëåéíà-Ãåíîõà
  • ÏÙÆ — ïàðàùèòîâèäíûå æåëåçû
  • ÏÝÒ — ïîçèòðîííî-ýìèññèîííàÿ òîìîãðàôèÿ ð/ — ðàç â ... (ñ, ìèí, ÷, ñóò è ò.ï.)
  • ÐÀ — ðåâìàòîèäíûé àðòðèò
  • ÐÀÀÑ — ðåíèí-àíãèîòåíçèí-àëüäîñòåðîíîâàÿ ñèñòåìà ðàçã. — ðàçãîâîðíîå ðàçë. — ðàçëè÷íîå
  • ÐÀÑ — ðàññòðîéñòâî àóòèñòè÷åñêîãî ñïåêòðà
  • ÐÄÑ — ðåñïèðàòîðíûé äèñòðåññ-ñèíäðîì ðèì. — ðèìñêèé
  • ÐÈÔ — ðåàêöèÿ èììóíîôëþîðåñöåíöèè
  • ÐÊÈ — ðàíäîìèçèðîâàííûå êëèíè÷åñêèå èññëåäîâàíèÿ
  • ÐÊÌÏ — ðåñòðèêòèâíàÿ êàðäèîìèîïàòèÿ
  • ÐÈÃÀ — ðåàêöèÿ íåïðÿìîé ãåìàããëþòèíàöèè
  • ÐÍ - ðåòèíîïàòèÿ íåäîíîøåííûõ
  • ÐÍÊ — ðèáîíóêëåèíîâàÿ êèñëîòà
  • ÐÍÏ - ðåêîìåíäóåìóþ íîðìó ïîòðåáëåíèÿ
  • ÐÎÃÊ — ðåíòãåíîãðàôèÿ (ðåíòãåíîãðàììà) îðãàíîâ ãðóäíîé êëåòêè
  • ÐÎËÑÍÑ — ðåêîìåíäàöèè ïî îöåíêå è ëå÷åíèþ ïðè ñîðòèðîâêå â íåîòëîæíûõ ñèòóàöèÿõ
  • ÐÏÃÀ — ðåàêöèÿ ïðÿìîé ãåìàããëþòèíàöèè
  • ð-ð — ðàñòâîð
  • ð-ðèòåëü — ðàñòâîðèòåëü
  • ÐÐÊ — ðåöåïòîðû ðåòèíîåâîé êèñëîòû
  • PPM — ðàñøèðåííûå ðåàíèìàöèîííûå ìåðîïðèÿòèÿ
  • ÐÑÂ — ðåñïèðàòîðíî-ñèíöèòèàëüíûé âèðóñ
  • ÐÑÄ — ðàññòðîéñòâî ñòåðåîòèïíûõ äâèæåíèé
  • ÐÑÊ — ðåàêöèÿ ñâÿçûâàíèÿ êîìïëåìåíòà
  • ÐÑÏ - ðàñ÷åòíàÿ ñðåäíÿÿ ïîòðåáíîñòü
  • ÐÒÃÀ — ðåàêöèÿ òîðìîæåíèÿ ãåìàããëþòèíàöèè
  • ÐÒÍÃÀ — ðåàêöèÿ òîðìîæåíèÿ íåïðÿìîé ãåìàããëþòèíàöèè
  • ÐÔ — Ðîññèéñêàÿ Ôåäåðàöèÿ
  • ÐÕÐ — ðåòèíîåâûå Õ-ðåöåïòîðû
  • Ð×À — ðàäèî÷àñòîòíàÿ àáëÿöèÿ
  • ÐÝÑ — ðåòèêóëîýíäîòåëèàëüíàÿ ñèñòåìà
  • ñ — ñåêóíäà
  • ñâ-âî — ñâîéñòâî
  • ÑÀÌ - ñèíäðîì àñïèðàöèè ìåêîíèÿ
  • ÑÂÄÑ — ñèíäðîì âíåçàïíîé äåòñêîé ñìåðòè
  • ÑÃß — ñèíäðîì ãèïåðñòèìóëÿöèè ÿè÷íèêîâ
  • ÑÄ — ñàõàðíûé äèàáåò
  • ÑÄ-1 — ñàõàðíûé äèàáåò 1-ãî òèïà
  • ÑÄ-2 — ñàõàðíûé äèàáåò 2-ãî òèïà
  • ÑÄÂÃ — ñèíäðîì äåôèöèòà âíèìàíèÿ è ãèïåðàêòèâíîñòè
  • ÑÅ — ñóáúåäèíèöà
  • ÑÆÊ — ñâîáîäíûå æèðíûå êèñëîòû
  • ÑÇÄ - ñëóæáà çàùèòû äåòåé
  • ÑÇÑÒ — ñèñòåìíîå(ûå) çàáîëåâàíèå(ÿ) ñîåäèíèòåëüíîé òêàíè
  • ÑÈÇ — ñðåäñòâà èíäèâèäóàëüíîé çàùèòû
  • ÑÈÎÇÑ— ñåëåêòèâíûé èíãèáèòîð îáðàòíîãî çàõâàòà ñåðîòîíèíà
  • ÑÈÎÇÑÍ — ñåëåêòèâíûå èíãèáèòîðû îáðàòíîãî çàõâàòà ñåðîòîíèíà è íîðýïèíåôðèíà
  • ÑÊÀ — ñåðïîâèäíî-êëåòî÷íàÿ àíåìèÿ
  • ÑÊ — ñåðïîâèäíî-êëåòî÷íàÿ áîëåçíü
  • ÑÊ — ñèñòåìíàÿ êðàñíàÿ âîë÷àíêà
  • ÑÊÔ — ñêîðîñòü êëóáî÷êîâîé ôèëüòðàöèè
  • ÑËÐ — ñåðäå÷íî-ëåãî÷íàÿ ðåàíèìàöèÿ
  • ñì — ñàíòèìåòð
  • ñì âîä.ñò. — ñàíòèìåòð âîäÿíîãî ñòîëáà
  • ÑÌÆ — ñïèííîìîçãîâàÿ æèäêîñòü
  • ÑÌÈ — ñðåäñòâà ìàññîâîé èíôîðìàöèè
  • ÑÌÎ — ñòðàõîâàÿ ìåäèöèíñêàÿ îðãàíèçàöèÿ
  • ÑÌÏ — ñêîðàÿ ìåäèöèíñêàÿ ïîìîùü
  • ÑÌÝ — ñóäåáíî-ìåäèöèíñêàÿ ýêñïåðòèçà
  • ÑÍ — ñåðäå÷íàÿ íåäîñòàòî÷íîñòü
  • ÑÍÑÀÄÃ — ñèíäðîì íåàäåêâàòíîé ñåêðåöèè ÀÄÃ
  • ÑÎÀÑ — ñèíäðîì îáñòðóêòèâíîãî àïíîý ñíà (âî ñíå) ñîâð. — ñîâðåìåííûé
  • ÑÎÝ — ñêîðîñòü îñåäàíèÿ ýðèòðîöèòîâ
  • ÑÏÈÄ — ñèíäðîì ïðèîáðåòåííîãî èììóíîäåôèöèòà
  • ÑÏÊß — ñèíäðîì ïîëèêèñòîçíûõ ÿè÷íèêîâ
  • ÑÏÎÍ — ñèíäðîì ïîëèîðãàííîé íåäîñòàòî÷íîñòè
  • ÑÐÂ — Ñ-ðåàêòèâíûé áåëîê
  • ÑÐÊ — ñèíäðîì ðàçäðàæåííîãî êèøå÷íèêà
  • ÑðÑÄ — ñðåäíÿÿ ñóòî÷íàÿ äîçà
  • ÑÑÂ — ñèíäðîì Ñòåðäæà-Âåáåðà
  • ÑÑÂÐ — ñèíäðîì ñèñòåìíîé âîñïàëèòåëüíîé ðåàêöèè
  • ÑÑÇ — ñåðäå÷íî-ñîñóäèñòûå çàáîëåâàíèÿ
  • ÑÑÑ — ñåðäå÷íî-ñîñóäèñòàÿ ñèñòåìà
  • ÑÑÑÓ — ñèíäðîì ñëàáîñòè ñèíóñîâîãî óçëà
  • ÑÒ — Ñèíäðîì Òóðåòòà
  • ÑÒÃ — ñîìàòîòðîïíûé ãîðìîí
  • ÑÒÐ — ñòîéêîå (õðîíè÷åñêîå) ìîòîðíîå èëè âîêàëüíîå òèêîçíîå ðàññòðîéñòâî
  • ñóò — ñóòêè
  • ÑÕÓ — ñèíäðîì õðîíè÷åñêîé óñòàëîñòè
  • ò.ä. — òàê äàëåå
  • ò.å. — òî åñòü
  • ò.ê. — òàê êàê
  • ò.î. — òàêèì îáðàçîì
  • ò.ï. — òîìó ïîäîáíîå
  • Ò3 — òðèéîäòèðîíèí
  • Ò4 — òèðîêñèí
  • ÒÀÍÊ — òåñò àìïëèôèêàöèè íóêëåèíîâûõ êèñëîò
  • ÒÁÑ — òàçîáåäðåííûé ñóñòàâ
  • ÒÃÂ — òðîìáîç ãëóáîêèõ âåí
  • ÒÃÑÊ — òðàíñïëàíòàöèÿ ãåìîïîýòè÷åñêèõ ñòâîëîâûõ êëåòîê
  • ÒÈÀ — òðàíçèòîðíàÿ èøåìè÷åñêàÿ àòàêà
  • ÒÈÀÁ — òîíêîèãîëüíàÿ àñïèðàöèîííàÿ áèîïñèÿ
  • ÒÌÎ — òâåðäàÿ ìîçãîâàÿ îáîëî÷êà
  • TH — òîðãîâîå íàèìåíîâàíèå ëåêàðñòâåííûõ ñðåäñòâ
  • ÒÏÃÃ — òåððèòîðèàëüíàÿ ïðîãðàììà ãîñóäàðñòâåííûõ ãàðàíòèé îêàçàíèÿ ãðàæäàíàì ÐÔ áåñïëàòíîé ìåäèöèíñêîé ïîìîùè
  • ÒÏÌ — òðàâìàòè÷åñêîå ïîâðåæäåíèå ìîçãà
  • ÒÒ — òåìïåðàòóðà òåëà
  • ÒÒÃ — òèðåîòðîïíûé ãîðìîí
  • ÒÔÐ — òðàíñôîðìèðóþùèé ôàêòîð ðîñòà
  • ÒÖÀ — òðèöèêëè÷åñêèå àíòèäåïðåññàíòû
  • òûñ. — òûñÿ÷à
  • ÒÝÄ —òðàíçèòîðíàÿ ýðèòðîáëàñòîïåíèÿ äåòñêîãî âîçðàñòà
  • ÒÝËÀ — òðîìáîýìáîëèÿ ëåãî÷íîé àðòåðèè
  • ÒÝÎ — òðîìáîýìáîëè÷åñêèå îñëîæíåíèÿ
  • ÓÇÄÑ — óëüòðàçâóêîâîå äóïëåêñíîå ñêàíèðîâàíèå
  • ÓÇÈ — óëüòðàçâóêîâîå èññëåäîâàíèå
  • óñòàð. — óñòàðåâøåå
  • ÓÔ — óëüòðàôèîëåòîâûé
  • ÓÔÎ — óëüòðàôèîëåòîâîå îáëó÷åíèå
  • ÔÀÏ — ôåëüäøåðñêî-àêóøåðñêèé ïóíêò
  • ÔÂ — ôðàêöèÿ âûáðîñà
  • ÔÂÄ — ôóíêöèè âíåøíåãî äûõàíèÿ
  • ÔÆÅË — ôîðñèðîâàííàÿ æèçíåííàÿ åìêîñòü ëåãêèõ
  • ÔÇ — Ôåäåðàëüíûé çàêîí
  • ôèçèîë. — ôèçèîëîãè÷åñêèé
  • ÔÊ — ôóíêöèîíàëüíûé êëàññ
  • ÔÊÑ — ôèáðîêîëîíîñêîïèÿ
  • ÔÊÓ — ôåíèëêåòîíóðèÿ
  • ÔÍ — ôèçè÷åñêàÿ íàãðóçêà
  • ÔÈÎ — ôàêòîð íåêðîçà îïóõîëè
  • ÔÎÌÑ — ôåäåðàëüíûé ôîíä îáÿçàòåëüíîãî ìåäèöèíñêîãî ñòðàõîâàíèÿ
  • ÔÎÑ — ôîñôîðîðãàíè÷åñêèå ñîåäèíåíèÿ
  • ÔÏ — ôèáðèëëÿöèÿ ïðåäñåðäèé
  • ôð. — ôðàíöóçñêèé
  • ÔÑÃ — ôîëëèêóëîñòèìóëèðóþùèé ãîðìîí
  • ÔÝÃÄÑ — ôèáðîýçîôàãîãàñòðîäóîäåíîñêîïèÿ
  • ÕÁÏ — õðîíè÷åñêàÿ áîëåçíü ïî÷åê
  • ÕÃ× — õîðèîíè÷åñêèé ãîíàäîòðîïèí ÷åëîâåêà
  • ÕÄÍ — õðîíè÷åñêàÿ äûõàòåëüíàÿ íåäîñòàòî÷íîñòü
  • õèì. — õèìè÷åñêàÿ
  • ÕÍÇË —õðîíè÷åñêèå íåñïåöèôè÷åñêèå çàáîëåâàíèÿ ëåãêèõ
  • ÕÎÁË — õðîíè÷åñêàÿ îáñòðóêòèâíàÿ áîëåçíü ëåãêèõ
  • ÕÏÍ — õðîíè÷åñêàÿ ïî÷å÷íàÿ íåäîñòàòî÷íîñòü
  • ÕÑ — õîëåñòåðèí
  • ÕÑÍ — õðîíè÷åñêàÿ ñåðäå÷íàÿ íåäîñòàòî÷íîñòü
  • XT — õèìèîòåðàïèÿ
  • ÖÂÄ — öåíòðàëüíîå âåíîçíîå äàâëåíèå
  • ÖÂÊ — öåíòðàëüíûé âåíîçíûé êàòåòåð
  • ÖÈÊ — öèðêóëèðóþùèå èììóííûå êîìïëåêñû
  • ÖÌÂ — öèòîìåãàëîâèðóñ
  • ÖÍÑ — öåíòðàëüíàÿ íåðâíàÿ ñèñòåìà
  • ÖÎÃ — öèêëîîêñèãåíàçà
  • ÖÏÄ — öåðåáðàëüíîå ïåðôóçèîííîå äàâëåíèå
  • ÖÑÒÑ — öåðåáðàëüíûé ñîëüòåðÿþùèé ñèíäðîì ÷ — ÷àñ
  • ×Ä — ÷àñòîòà äûõàíèÿ
  • ×ÄÄ — ÷àñòîòà äûõàòåëüíûõ äâèæåíèé
  • ×Ê — ÷ðåñêîæíîå êîðîíàðíîå âìåøàòåëüñòâî
  • ×ÌÍ — ÷åðåïíî-ìîçãîâûå íåðâû
  • ×ÌÒ — ÷åðåïíî-ìîçãîâàÿ òðàâìà
  • ×Í — ÷åðåïíûå íåðâû
  • ×Ñ — ÷óâñòâèòåëüíîñòü/ñïåöèôè÷íîñòü (×Ñ 97%/87%)
  • ×ÑÑ — ÷àñòîòà ñåðäå÷íûõ ñîêðàùåíèé
  • ×ÑÑÏ - ÷àñòîòà ñåðäå÷íûõ ñîêðàùåíèé ïëîäà
  • ×Ò — ÷àñòè÷íîå òðîìáîïëàñòèíîâîå âðåìÿ
  • ØÊÃ — øêàëà êîìû Ãëàçãî
  • ØÎÏ — øåéíûé îòäåë ïîçâîíî÷íèêà
  • ÙÆ — ùèòîâèäíàÿ æåëåçà
  • ÃÖÔ — ùåëî÷íàÿ ôîñôàòàçà
  • ÝÀÐ — ýêâèâàëåíò àêòèâíîñòè ðåòèíîëà
  • ÝÄÒÀ — ýòèëåíäèàìèíòåòðàóêñóñíàÿ êèñëîòà (ýòèëåíäèàìèíòåòðààöåòàò)
  • ÝÊÃ — ýëåêòðîêàðäèîãðàôèÿ
  • ÝÊÌÎ — ýêñòðàêîðïîðàëüíàÿ ìåìáðàííàÿ îêñèãåíàöèÿ
  • ÝÊÎ — ýêñòðàêîðïîðàëüíîå îïëîäîòâîðåíèå
  • ÝÊÑ — ýëåêòðîêàðäèîñòèìóëÿòîð, ýëåêãðîêàðäèîñòèìóëÿöèÿ
  • ÝÌÃ — ýëåêòðîìèîãðàôèÿ
  • ÝÌÊ — ýëåêòðîííàÿ ìåäèöèíñêàÿ êàðòà
  • ÝÌÏ — ýêñòðåííàÿ ìåäèöèíñêàÿ ïîìîùü
  • ÝÍÌÏ — ýêñòðåííàÿ è íåîòëîæíàÿ ìåäèöèíñêàÿ ïîìîùü
  • ÝÍÌÒ — ýêñòðåìàëüíî íèçêàÿ ìàññà òåëà
  • ÝÒÒ — ýíäîòðàõåàëüíàÿ òðóáêà
  • ÝõîÊà — ýõîêàðäèîãðàôèÿ
  • ÝÝÃ — ýëåêòðîýíöåôàëîãðàôèÿ
  • ÞÄÌ — þâåíèëüíûé äåðìàòîìèîçèò
  • ÞÈÀ — þâåíèëüíûé èäèîïàòè÷åñêèé àðòðèò
  • ßÁ — ÿçâåííàÿ áîëåçíü
  • ÀÀ — àìèëîèä A (amyloid À)
  • ÀÀÐ — Àìåðèêàíñêàÿ àêàäåìèÿ ïåäèàòðèè (American Academy of Pediatrics)
  • ABC — àëãîðèòì íåîòëîæíîé ïîìîùè «äûõàòåëüíûå ïóòè-äûõàíèå-êðîâîîáðàùåíèå» (Airways-Breathing-Circulation)
  • ÀÂÑÀ3 — áåëêîâûé ÷ëåí ÀÒÔ-ñâÿçûâàþùåé êàññåòû À3
  • ÀÂÑÂ11— ãåí ÀÒÔ-ñâÿçûâàþùåé êàññåòû, 11-é ÷ëåí ïîäñåìåéñòâà  (ATP-binding cassette, sub-family  member 11)
  • ÀÂÑÂ4 — ãåí ÀÒÔ-ñâÿçûâàþùåé êàññåòû, 4-é ÷ëåí ïîäñåìåéñòâà  (ATP-binding cassette 4 gene)
  • ÀÂÑÑ2 — ãåí, êîäèðóþùèé 2-é ÷ëåí ïîäñåìåéñòâà Ñ ÀÒÔ-ñâÿçûâàþùèõ êàññåò (ATP-binding cassette sub-family Ñ member 2)
  • ABCDE — àëãîðèòì íåîòëîæíîé ïîìîùè «äûõàòåëüíûå ïóòè-äûõàíèå-êðîâîîáðàùåíèå-íåâðîëîãè÷åñêèé ñòàòóñ-âíåøíèé âèä» (Airways-Breathing-Circulation-Disability- Exposure)
  • ABCG5/G8 — ãåòåðîäèìåð ïåðåíîñ÷èêà ÀÒÔ-ñâÿçûâàþùåé êàññåòû ABCG5 è ABCG8 (The heterodimer of ATP-binding cassette transporter ABCG5 and ABCG8)
  • AC — äî åäû (ïðè íàçíà÷åíèÿõ) — ante cibum
  • ÀÑÅÐ — Àìåðèêàíñêàÿ êîëëåãèÿ âðà÷åé íåîòëîæíîé ïîìîùè (American College of Emergency Physicians)
  • ACOG — Àìåðèêàíñêàÿ êîëëåãèÿ àêóøåðîâ è ãèíåêîëîãîâ (American College of Obstetricians and Gynecologists)
  • AHA — Àìåðèêàíñêàÿ êàðäèîëîãè÷åñêàÿ àññîöèàöèÿ (American Heart Association)
  • ALTE — î÷åâèäíîå îïàñíîå äëÿ æèçíè ñîáûòèå (apparent life-threatening event)
  • APLS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè, ñïîíñèðóåìûå Àìåðèêàíñêîé àêàäåìèåé ïåäèàòðèè è Àìåðèêàíñêîé êîëëåãèåé âðà÷åé íåîòëîæíîé ïîìîùè (Advanced Pediatric Life Support)
  • ARPKD — àóòîñîìíî-ðåöåññèâíûé ïîëèêèñòîç ïî÷åê
  • ASCVD-ðèñê — ðèñê ðàçâèòèÿ àòåðîñêëåðîòè÷åñêîãî ñåðäå÷íî-ñîñóäèñòîãî çàáîëåâàíèÿ (ArterioSclerotic Cardiovascular Disease, ASCVD)
  • AVPU — øêàëà äëÿ îöåíêè óðîâíÿ ñîçíàíèÿ («â ÿñíîì ñîçíàíèè»; «ðåàêöèÿ íà âåðáàëüíûå ðàçäðàæèòåëè»; «ðåàêöèÿ íà áîëü»; «áåç ñîçíàíèÿ») (alert, verbal, pain, unresponsive)
  • BCS — ìèòîõîíäðèàëüíûé øàïåðîí BCS1 (mitochondrial chaperone BCS1)
  • BIN — áèíîìèíàëüíàÿ íîìåíêëàòóðà «æèâîé» ïðèðîäû
  • BiPAP — ðåæèì èñêóññòâåííîé âåíòèëÿöèè ëåãêèõ ñ äâóìÿ óðîâíÿìè ïîëîæèòåëüíîãî äàâëåíèÿ (bilevel positive airway pressure) = ÂÐÀÐ
  • BNP — íàòðèéóðåòè÷åñêèé ïåïòèä Â-òèïà — ìîçãîâîé ( (brain)-type natriuretic peptide)
  • BRUE — áûñòðî ðàçðåøèâøèåñÿ íåîáúÿñíèìûå ñîáûòèÿ (Brief resolved unexplained events)
  • BSEP — íàñîñ âûâåäåíèÿ ñîëåé æåë÷íûõ êèñëîò
  • CADASIL — öåðåáðàëüíàÿ àóòîñîìíî-äîìèíàíòíàÿ àðòåðèîïàòèÿ ñ ïîäêîðêîâûìè èíôàðêòàìè è ëåéêîýíöåôàëîïàòèåé (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
  • CAPS — êðèîïèðèí-àññîöèèðîâàííûé ïåðèîäè÷åñêèé ñèíäðîì (cryopyrin-associated periodic syndrome)
  • CBIT — êîìïëåêñíîå ïîâåäåí÷åñêîå âîçäåéñòâèå ïðè òèêàõ (Comprehensive behavioral intervention for tics)
  • CD — êëàñòåðû äèôôåðåíöèðîâêè (clusters of differentiation)
  • CDC — Öåíòð ïî êîíòðîëþ è ïðîôèëàêòèêå çàáîëåâàíèé, ÑØÀ (Center for Disease Control and Prevention)
  • CDG — âðîæäåííûå íàðóøåíèÿ ãëèêîçèëèðîâàíèÿ (Congenital Disorder of Glycosylation)
  • CFTR — òðàíñìåìáðàííûé ðåãóëÿòîð ìóêîâèñöèäîçà (cystic fibrosis transmembrane regulator)
  • CH — ãåìîëèòè÷åñêèé êîìïëåìåíò (hemolytic complement)
  • CLLS — øêàëà îöåíêè îñòðîé ãîðíîé áîëåçíè îçåðà Ëóèç ó äåòåé (Childrens Lake Louise Score)
  • CMT — Øàðêî-Ìàðè-Òóòà áîëåçíü (Charcot-Marie-Tooth disease)
  • ÑÐÀÐ — ïîñòîÿííîå ïîëîæèòåëüíîå äàâëåíèå â äûõàòåëüíûõ ïóòÿõ (Constant Positive Airway Pressure)
  • CYP — öèòîõðîì îáùèé
  • DAF — ôàêòîð óñêîðåíèÿ ðàñïàäà (decay-accelerating factor)
  • DGAT1 —äèàöèëãëèöåðèí-1-àöèëòðàíñôåðàçà (diacylglycerol acyltransferase 1)
  • DHR — äèãèäðîðîäàìèí (dihydrorhodamine)
  • DSM — Äèàãíîñòè÷åñêîå è ñòàòèñòè÷åñêîå ðóêîâîäñòâî ïî ïñèõè÷åñêèì ðàññòðîéñòâàì (Diagnostic and Statistical Manual of Mental Disorders)
  • EAST syndrome — ýïèëåïñèÿ, àòàêñèÿ, ñåíñîíåâðàëüíàÿ òóãîóõîñòü è òóáóëîïàòèÿ (epilepsy, ataxia, sensorineural hearing loss, and tubulopath)
  • EBM — äîêàçàòåëüíàÿ ìåäèöèíà (Evidence based medicine)
  • EPCAM— ìîëåêóëà àäãåçèè ýïèòåëèàëüíûõ êëåòîê (epithelial cell adhesion molecule)
  • ESC — Åâðîïåéñêîå îáùåñòâî êàðäèîëîãèè (European Society of Cardiology)
  • EXIT — ëå÷åíèå âíå ìàòêè âî âðåìÿ ðîäîâ (Ex utero intrapartum treatment)
  • FAST — ñôîêóñèðîâàííàÿ ñîíîãðàôèÿ áðþøíîé ïîëîñòè ïðè òðàâìå (focused assessment with sonography in trauma)
  • FDA — Êîìèòåò ïî êîíòðîëþ çà ëåêàðñòâåííûìè âåùåñòâàìè è ïèùåâûìè äîáàâêàìè, ÑØÀ (Food and Drug Administration)
  • FFR — ôðàêöèîííûé ðåçåðâ êðîâîòîêà (Fractional Flow Reserve)
  • FGF-23 — ôàêòîð ðîñòà ôèáðîáëàñòîâ-23 (Fibroblast growth factor-23)
  • FIC 1 —ñåìåéíûé âíóòðèïå÷åíî÷íûé õîëåñòàç 1-ãî òèïà, áîëåçíü Áàéëåðà (familial intrahepatic cholestasis)
  • FiO2 — ôðàêöèÿ êèñëîðîäà (âî âäûõàåìîì âîçäóõå, ãàçîâîé ñìåñè)
  • FISH — ôëóîðåñöåíòíàÿ in situ ãèáðèäèçàöèÿ (fluorescence in situ hybridization)
  • FLAIR — âîññòàíîâëåíèå èíâåðñèè ñ îñëàáëåíèåì æèäêîñòè (fluid-attenuated inversion recovery)
  • FMF — ñåìåéíàÿ ñðåäèçåìíîìîðñêàÿ ëèõîðàäêà (Familial Mediterranean fever)
  • GATA — gata-ñâÿçûâàþùèé áåëîê
  • HADH — ãèäðîêñèëàöèë-ÊîÀ-äåãèäðîãåíàçà (Hydro-xyacyl-Coenzyme A dehydrogenase)
  • HAV — âèðóñ ãåïàòèòà Â (hepatitis A virus)
  • Hb — ãåìîãëîáèí
  • HBcAg — ñåðäöåâèííûé àíòèãåí âèðóñà ãåïàòèòà Â
  • HBeAg — àíòèãåí âèðóñà ãåïàòèòà Â
  • HBsAg — ïîâåðõíîñòíûé àíòèãåí âèðóñà ãåïàòèòà Â
  • HBV — âèðóñ ãåïàòèòà  (hepatitis  virus)
  • HCV — âèðóñ ãåïàòèòà Ñ (hepatitis Ñ virus)
  • HDV — âèðóñ ãåïàòèòà D (hepatitis D virus)
  • HFNC — íàçàëüíûå êàíþëè âûñîêîãî ïîòîêà (heated, high-flow nasal cannula)
  • Hib — ãåìîôèëüíàÿ ïàëî÷êà òèïà  (Haemophilus influenzae  type)
  • HLA — ëåéêîöèòàðíûå àíòèãåíû (ãëàâíîãî êîìïëåêñà ãèñòîñîâìåñòèìîñòè) ÷åëîâåêà (human leukocyte antigens)
  • HR — îòíîøåíèå ðèñêîâ (hazard ratio)
  • HRT — òåðàïèÿ îòìåíû ïðèâû÷êè (Habit reversal therapy)
  • Ht — ãåìàòîêðèò
  • HTLV — Ò-ëèìôîòðîïíûé âèðóñ ÷åëîâåêà (human T-lymphotropic virus)
  • Ig — èììóíîãëîáóëèí
  • IgA — èììóíîãëîáóëèí A
  • IgE — èììóíîãëîáóëèí E
  • IgG — èììóíîãëîáóëèí G
  • IgM — èììóíîãëîáóëèí M
  • IL — èíòåðëåéêèí
  • IPEX — Õ-ñöåïëåííûé ñèíäðîì èììóííîé äèñðå-ãóëÿöèè, ïîëèýíäîêðèíîïàòèè è ýíòåðîïàòèè (Immunedysregulation polyendocrinopathy enteropathy, X-linked)
  • IQ — êîýôôèöèåíò óìñòâåííîãî ðàçâèòèÿ (intelligence quotient)
  • JAK — ÿíóñ-êèíàçà (Janus kinase)
  • LFA — àíòèãåí, àêòèâèðóþùèé ôóíêöèþ ëåéêîöèòîâ (Lymphocyte function-associated antigen)
  • LT — ëåéêîòðèåí
  • MALT — ëèìôîèäíàÿ òêàíü ñëèçèñòîé îáîëî÷êè (mucosa-associated lymphoid tissue)
  • MASP — ÌÑË-àññîöèèðîâàííàÿ ñåðèíîâàÿ ïðîòåàçà (MBL-associated serine protease)
  • MBL — ìàííîçî-ñâÿçûâàþùèé ëåêòèí (mannose-
  • binding lectin)
  • MCP — ìåìáðàííûé áåëîê-êîôàêòîð (membrane cofactor protein)
  • MDR3 — áåëîê ìíîæåñòâåííîé ëåêàðñòâåííîé óñòîé÷èâîñòè 3 (multidrug resistance protein 3)
  • MELAS — ìèòîõîíäðèàëüíàÿ ýíöåôàëîïàòèÿ, ëàêòîàöèäîç è èíñóëüòîïîäîáíûå ýïèçîäû (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
  • MERRF — ìèîêëîíè÷åñêàÿ ýïèëåïñèÿ ñ ðâàíûìè êðàñíûìè âîëîêíàìè (Myoclonic epilepsy with ragged red fibers)
  • Mr — êàæóùàÿñÿ ìîëåêóëÿðíàÿ ìàññà
  • MRP — áåëîê ñ ìíîæåñòâåííîé ëåêàðñòâåííîé óñòîé÷èâîñòüþ (multidrug-resistant protein)
  • MRSA — ìåòèöèëëèíðåçèñòåíòíûé çîëîòèñòûé ñòàôèëîêîêê
  • MSSA — ìåòèöèëëèí÷óâñòâèòåëüíûé çîëîòèñòûé ñòàôèëîêîêê
  • NB! — âàæíî, îáðàòèòü âíèìàíèå (Nota bene)
  • NICE — Íàöèîíàëüíûé èíñòèòóò çäîðîâüÿ è êëèíè÷åñêîãî ñîâåðøåíñòâîâàíèÿ (êà÷åñòâà ìåäèöèíñêîé ïîìîùè) Âåëèêîáðèòàíèè (National Institute for Health and Clinical Excellence)
  • NK — åñòåñòâåííûå êëåòêè-êèëëåðû (natural killer)
  • NMDA — N-ìåòèë-D-àñïàðòàò (N-methyl-D-aspartate)
  • NMDA — N-ìåòèë-D-àñïàðòàòíûå ðåöåïòîðû
  • NNT — ÷èñëî áîëüíûõ, êîòîðûõ íåîáõîäèìî ïðîëå÷èòü, ÷òîáû äîñòè÷ü êàêîãî-òî óêàçàííîãî ýôôåêòà (Number Need to Treatment)
  • OR — îòíîøåíèå øàíñîâ (odds ratio)
  • paCO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà â àðòåðèàëüíîé êðîâè
  • PALS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè (Pediatric Advanced Life Support)
  • PANDAS — àóòîèììóííîå íåéðîïñèõèàòðè÷åñêîå ðàññòðîéñòâî â äåòñêîì âîçðàñòå, àññîöèèðîâàííîå ñî ñòðåïòîêîêêîâîé èíôåêöèåé (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
  • PANS — îñòðûé íåéðîïñèõèàòðè÷åñêèé ñèíäðîì â äåòñêîì âîçðàñòå (Pediatric acute-onset neuropsychiatric syndrome)
  • paO2 — ïàðöèàëüíîå äàâëåíèå êèñëîðîäà â àðòåðèàëüíîé êðîâè
  • PAS — ôóêñèíñåðíèñòàÿ êèñëîòà, ðåàêòèâ Øèôôà (periodic acid-Shiff)
  • PC — ïîñëå åäû (ïðè íàçíà÷åíèÿõ) — post cibum ðÑO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà
  • PCSK-9 — ïðîïðîòåèíîâàÿ êîíâåðòàçà ñóáòèëèçèí-êåêñè-íîâîãî òèïà 9 (proprotein convertase subtilisin/ kexin type 9)
  • PFAPA — ïåðèîäè÷åñêàÿ ëèõîðàäêà ñ àôòîçíûì ñòîìàòèòîì, ôàðèíãèòîì è ëèìôàäåíèòîì (Periodic Fevers with Aphthous stomatitis, Pharyngitis and Adenitis)
  • PFIC — ñåìåéíûé âíóòðèïå÷åíî÷íûé õîëåñòàç (familial intrahepatic cholestasis)
  • Pg — ïðîñòàãëàíäèí
  • pH — âîäîðîäíûé ïîêàçàòåëü
  • PIM — ïîêàçàòåëü ëåòàëüíîãî èñõîäà ó äåòåé (Pediatric Index of Mortality)
  • piO2 — ïàðöèàëüíîå äàâëåíèå êèñëîðîäà âî âäûõàåìîì
  • âîçäóõå
  • ðO2 — ïàðöèàëüíîå äàâëåíèå êèñëîðîäà
  • POLG — ñóáúåäèíèöà ÄÍÊ-ïîëèìåðàçû ó
  • PRISA II — îöåíêà ðèñêà ãîñïèòàëèçàöèè ó äåòåé II (Pediatric Risk of Admission)
  • PRISM — ðèñê ëåòàëüíîãî èñõîäà ó äåòåé (Pediatric Risk of Mortality)
  • PRN — ïðè (ïî) íåîáõîäèìîñòè (Pro re nata — ïðè âîçíèêíîâåíèè îáñòîÿòåëüñòâ)
  • PRSS — ãåí ñåðèíîâîé ïðîòåàçû
  • PS. — ïðèìå÷àíèå (Post scriptum)
  • PUVA-òåðàïèÿ — ïñîðàëåí-óëüòðàôèîëåò À-òåðàïèÿ (psoralen and ultraviolet À)
  • Q#H — êàæäûå # ÷àñîâ (ïðè íàçíà÷åíèÿõ) — quaque ... hora
  • QAM — êàæäîå óòðî (ïðè íàçíà÷åíèÿõ) — quaque ante meridiem
  • QPM — êàæäûé âå÷åð (ïðè íàçíà÷åíèÿõ) — quaque post meridiem
  • RAG — ãåí, àêòèâèðóþùèé ðåêîìáèíàçó
  • RePEAT— ïåðåñìîòðåííûé èíñòðóìåíò äëÿ îöåíêè ïåäèàòðè÷åñêîé íåîòëîæíîé ìåäèöèíñêîé ïîìîùè (Revised Pediatric Emergency Assessment Tool)
  • RF — ðåâìàòîèäíûé ôàêòîð
  • Rh — ðåçóñ(-ôàêòîð)
  • Rh«-» — ðåçóñ-îòðèöàòåëüí(ûé)
  • Rh«+» — ðåçóñ-ïîëîæèòåëüí(ûé)
  • ROHHAD — áûñòðî ðàçâèâàþùååñÿ îæèðåíèå ñ äèñôóíêöèåé ãèïîòàëàìóñà, ãèïîâåíòèëÿöèåé è ñïîíòàííîé äèñðåãóëÿöèåé (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
  • RR — îòíîñèòåëüíûé ðèñê (relative risk èëè risk ratio) RW — ðåàêöèÿ Âàññåðìàíà (reaction of Wassermann)
  • SaO2 — ñàòóðàöèÿ àðòåðèàëüíîé êðîâè êèñëîðîäîì SatO2 — íàñûùåíèå êðîâè êèñëîðîäîì
  • ScvO2 — íàñûùåíèå êèñëîðîäîì öåíòðàëüíîé âåíîçíîé êðîâè (Central venous oxygen saturation)
  • SD — ñòàíäàðòíîå îòêëîíåíèå (standart deviation) SFTPA — ãåí ñóðôàêòàíòíîãî áåëêà A
  • SFTPB — ãåí ñóðôàêòàíòíîãî áåëêà Â
  • SFTPC — ãåí ñóðôàêòàíòíîãî áåëêà Ñ
  • SPINK — èíãèáèòîð ñåðèíîâîé ïðîòåàçû
  • SpO2 — íàñûùåíèå (ñàòóðàöèÿ) ãåìîãëîáèíà êèñëîðîäîì spp. — âèäû (ïðè ðîäîâîì èìåíè ìèêðîîðãàíèçìîâ)
  • Src. — èñòî÷íèê èíôîðìàöèè, áèáëèîãðàôè÷åñêàÿ ññûëêà (source)
  • STAT1 — ñèãíàëüíûé ïðåîáðàçîâàòåëü è àêòèâàòîð òðàíñêðèïöèè 1 (signal transducer and activator of transcription)
  • TA — ìåæäóíàðîäíàÿ àíàòîìè÷åñêàÿ òåðìèíîëîãèÿ TCR — T-êëåòî÷íûé ðåöåïòîð (T-cell receptor)
  • TLRs — Òîëë-ïîäîáíûå ðåöåïòîðû (Toll-like receptors) TNF — ôàêòîð íåêðîçà îïóõîëè (tumor necrosis factor)
  • TORCH — òîêñîïëàçìîç, êðàñíóõà, öèòîìåãàëîâèðóñíàÿ èíôåêöèÿ, ãåðïåñ è äðóãèå èíôåêöèè (Toxoplasmosis, Other infections, Rubella, Cytomegalovirus Herpes simplex)
  • TPM — ìóòàöèÿ òðîïîìèîçèíà (mutation of the tropomyosin)
  • TRAP — ñèíäðîì îáðàòíîé àðòåðèàëüíîé ïåðôóçèè áëèçíåöîâ (twin reversed arterial perfusion)
  • TRAPS — ïåðèîäè÷åñêèé ñèíäðîì, àññîöèèðîâàííûé ñ ðåöåïòîðîì ôàêòîðà íåêðîçà îïóõîëè (Tumor Necrosis Factor Receptor-Associated Periodic Syndrome)
  • ™ — òîðãîâàÿ ìàðêà
  • URL — èíòåðíåò-ññûëêà, àäðåñ èíòåðíåò-ðåñóðñà (Uniform Resource Locator)
  • VEGF — ôàêòîð ðîñòà ýíäîòåëèÿ ñîñóäîâ (Vascular Endothelial Growth Factor)
  • WPW — ñèíäðîì Âîëüôà-Ïàðêèíñîíà-Óàéòà (Wolff-Parkinson-White)
  • XLA — Õ-ñöåïëåííàÿ àãàììàãëîáóëèíåìèÿ (X-linked agammaglobulinemia)
  • aDG-RD — äèñòðîôèè, ñâÿçàííûå ñ a-äèñòðîãëèêàíàìè (alpha dystroglycan-related dystrophies)
  • β-ÕÃ× — β-ñóáúåäèíèöà õîðèîíè÷åñêîãî ãîíàäîòðîïèíà ÷åëîâåêà

 õîäå ïîäãîòîâêè ñòàòåé ïî äåòñêîé óðîëîãèè â ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:

  1. Bayram MT, Alaygut D, Soylu A, et al. Clinical and radiological course of simple renal cysts in children. Urology. 2014;83:433–437.
  2. Je BK, Kim HK, Horn PS, et?al. Incidence and spectrum of renal complications and extrarenal diseases and syndromes in 380 children and young adults with horseshoe kidney. Am J Roentgenol. 2015;205:1306–1314.
  3. Karmazyn B, Tawadros A, Delaney LR, et al. Ultrasound classification of solitary renal cysts in children. J Pediatr Urol. 2015;11:149.e1–149.e6.
  4. La Scola C, Ammenti A, Puccio G, et al. Congenital solitary kidney in children: size matters. J Urol. 2016;196:1250–1256.
  5. Mansouri R, Sander JC, Janzen NK, et al. A case of obstructed hemivagina with ectopic ureter leading to severe hydrocolpos and contralateral renal outflow tract obstruction in a neonate. J Pediatr Adolesc Gynecol. 2015;28:e131–e133.
  6. Marzullo P, Guarino S, Grandone A, et al. Outcomes of a cohort of prenatally diagnosed and early enrolled patients with congenital solitary functioning kidney. J Urol. 2017;198:1153–1158.
  7. Naval-Baudin P, Carre?o Garc?a E, Sanchez Marquez A, et al. Multicystic seminal vesicle with ipsilateral renal agenesis: two cases of Zinner syndrome. Scand J Urol. 2017;51:81–84.
  8. Papagiannopoulos D, Gong E. Revisiting sports precautions in children with solitary kidneys and congenital anomalies of the kidney and urinary tract. Urology. 2017;101:9–14.
  9. Schlomer B, Rodriguez E, Baskin L. Obstructed hemivagina and ipsilateral renal agenesis (OHVIRA) syndrome should be redefined as ipsilateral renal anomalies: cases of symptomatic atrophic and dysplastic kidney with ectopic ureter to obstructed hemivagina. J Pediatr Urol. 2015;11:77.e1–77.e6.
  10. Siomou E, Giapros V, Papadopoulou F, et?al. Growth and function in childhood of a normal solitary kidney from birth or from early infancy. Pediatr Nephrol. 2014;29:249–256.
  11. Yavuz S, K?yak A, Sander S. Renal outcome of children with horseshoe kidney: a single-center experience. Urology. 2015;85:463–466.
  12. American Academy of Pediatrics Subcommittee on Urinary Tract infection, Reaf- firmation of AAP Clinical Practice Guideline. The diagnosis and management of the initial urinary tract infection in febrile infants and young children 2-24 months of age. Pediatrics. 2016;138(6):e2016–e3026.
  13. American Academy of Pediatrics Subcommittee on Urinary Tract Infection, Steering
  14. Committee on Quality Improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128:595–610.
  15. Bocquet N, Alaoui AS, Jais JP, et?al. Randomized trial of oral versus sequential IV/ oral antibiotic for acute pyelonephritis in children. Pediatrics. 2012;129:e269–e275.
  16. Chaudhari PP, Monuteaux MC, Bachur RG. êîíöåíòðàöèÿ ìî÷è è ïèóðèÿ äëÿ identifying UTI in infants. Pediatrics. 2017;138(5):e2016–e2370.
  17. Chen PC, Chang LY, Lu CY, et?al. Drug susceptibility and treatment response of common urinary tract infection pathogens in children. J Microbiol Immunol Infect. 2014;47:478–483.
  18. Coulthard MG, Lambert HJ, Vernon SJ, et al. Does prompt treatment of urinary tract infection in preschool children prevent renal scarring? Mixed retrospective and prospective audits. Arch Dis Child. 2014;99(4):342–347.
  19. Davis A, Obi B, Ingram M. Investing urinary tract infections in children. BMJ. 2013;346:35–37.
  20. Downs SM. UTI and watchful waiting: the courage to do nothing. Pediatrics. 2014.
  21. Elder JS, Diaz M. Vesicoureteral reflux: the role of bladder-bowel dysfunction. Nat Rev Urol. 2013;10:640–648.
  22. Fernondez MLH, Merino NG, Garcia AT, et?al. A new technique for fast and safe collection of urine in newborns. Arch Dis Child. 2013;98:27–29.
  23. Finnell SM, Carroll AE, Downs SM, Subcommittee on Urinary Tract Infection. Technical report—diagnosis and management of an initial UTI in febrile infants and young children. Pediatrics. 2011;128:e749–e770.
  24. Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ. 2013;346:30–33.
  25. Gupta S, Araya CE, Dharnidharka VR. Xanthogranulomatous pyelonephritis in pediatric patients: case report and review of literature. J Pediatr Urol. 2010;6:355–358.
  26. Hewitt IK, Montini G. Paediatric urology: rapid uptake of guidelines for imaging after first febrile UTI. Nat Rev Urol. 2013;10:622–624.
  27. Hewitt IK, Pennesi M, Morello W, et al. Antibiotic prophylaxis for urinary tract infection-related renal scarring: a systematic review. Pediatrics. 2017;139(5):e20163145.
  28. Hooten TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the infectious diseases society of America. Clin Infect Dis. 2010;50:625–663.
  29. Hooten TM, Roberts PL, Cox ME, et al. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013;369:1883–1891.
  30. Jackson EC.: Urinary tract infections in children: knowledge updates and a salute to the future. Pediatr Rev. 2015;36(4):153–164.
  31. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Sao Paulo Med J. 2013;131:363.
  32. Jerardi KE, Elkeeb D, Weiser J, et ?al. Rapid implementation of evidence-based guidelines for imaging after first urinary tract infection. Pediatrics. 2013;132:e749–e755.
  33. Johnson JR, Russo TA. Acute pyelonephritis in adults. N Engl J Med. 2018;378(1):48–58.
  34. Judkins A, Pascoe E, Payne D. Management of urinary tract infection in a tertiary children’s hospital before and after publication of the NICE guidelines. Arch Dis Child. 2013;98:521–525.
  35. Juliano TM, Stephany HA, Clayton DB, et? al. Incidence of abnormal imaging and recurrent pyelonephritis after first febrile urinary tract infection in children 2 to 24 months old. J Urol. 2013;190:1505–1510.
  36. Kaufman J, Fitzpatrick P, Tosif S, et ?al. Faster clean catch urine collection (quick-wee method) from infants: randomized controlled trial. BMJ. 2017;357:j1341.
  37. Kowalsky RH, Shah NB. Update on urinary tract infections in the emergency depart- ment. Curr Opin Pediatr. 2013;25:317–322.
  38. Kupelian AS, Horsley H, Khasriya R, et ?al. Discrediting microscopic pyuria and leucocyte esterase as diagnostic surrogates for infection in patients with lower urinary tract symptoms: results from a clinical and laboratory evaluation. BJU Int. 2013;112:231–238.
  39. La Scola C, De Mutiis C, Hewitt IK, et? al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics. 2013;131:e665–e671.
  40. Lavelle JM, Blackstone MM, Funari MK, et?al. Two-step process for ED UTI screening in febrile young children: reducing catheterization rates. Pediatrics. 2016;138(1):e20153023.
  41. Leroy S, Fernandez-Lopez A, Nikfar R, et?al. Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI. Pediatrics. 2013;131:870–879.
  42. Nelson CP, Johnson EK, Logvinenko T, et?al. Ultrasound as a screening test for genitourinary anomalies in children with UTI. Pediatrics. 2014;133:394–403.
  43. Paintsil E. Update on recent guidelines for the management of urinary tract infections in children: the shifting paradigm. Curr Opin Pediatr. 2013;25:88–94.
  44. Pauchard JY, Chehade H, Kies CZ, et? al. Avoidance of voiding cystourethrography in infants younger than 3 months with escherichia coli urinary tract infection and normal renal ultrasound. Arch Dis Child. 2017;102:804–808.
  45. Ristola MT, Hurme T. NICE guidelines for imaging studies in children with UTI adequate only in boys under the age of 6 months. Pediatr Surg Int. 2013;29:215–222.
  46. RIVUR Trial Investigators: Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med. 2014;370:2367–2376.
  47. Shah AP, Cobb BT, Lower DR, et ?al. Enhanced vs. automated urinalysis for screening of urinary tract infections in children in the emergency department. Pediatr Infect Dis J. 2014;33(3):272–275.
  48. Shaikh N, Craig JC, Rovers MM, et ?al. Identification of children and adolescents at risk for renal scarring after a first urinary tract infection—a meta-analysis with individual patient data. JAMA Pediatr. 2014;168(10):893–900.
  49. Shaikh N, Hoberman A, Keren R, et? al. Recurrent urinary tract infections with bladder and bowel dysfunction. Pediatrics. 2016;137(1):e20152982.
  50. Shaikh N, Mattoo TK, Keren R, et? al. Early antibiotic treatment for pediatric febrile urinary tract infection and renal scarring. JAMA Pediatr. 2016;170(9):848–854.
  51. Shaikh N, Shope TR, Hoberman A, et? al. Association between uropathogen and pyuria. Pediatrics. 2016;138(1):e20160087.
  52. Suson KD, Mathews R. Evaluation of children with urinary tract infection—impact of the 2011 AAP guidelines on the diagnosis of vesicoureteral reflux using a historical series. J Pediatr Urol. 2014.10(1):182–185.
  53. Tzimenatos L, Mahajan P, Dayan PS, et ?al. Accuracy of the urinalysis for urinary tract infections in febrile infants 60 days and younger. Pediatrics. 2018;141(2):e20173068.
  54. Wallace SS, Brown DN, Cruz AT. Prevalence of concomitant acute bacterial meningitis in neonates with febrile urinary tract infection: a retrospective cross-sectional study. J Pediatr. 2017;184:199–203.
  55. Wan J, Skoog SJ, Hulbert WC, et?al. Section on urology response to new guidelines for the diagnosis and management of UTI. Pediatrics. 2012;129:e1051–e1053.
  56. Wise GJ, Schlegel PN. Sterile pyuria. N Engl J Med. 2015;372(11):1048–1054.
  57. Alexander SE, Arlen AM, Storm DW, et? al. Bladder volume at onset of vesicoureteral reflux is an independent risk factor for breakthrough febrile urinary tract infection. J Urol. 2015;193:1342–1346.
  58. Arlen AM, Cooper CS. Controversies in the management of vesicoureteral reflux. Curr Urol Rep. 2015;16:64.
  59. Arlen AM, Garcia-Roig M, Weiss AD, et? al. Vesicoureteral reflux index: 2-institution analysis and validation. J Urol. 2016;195:1294–1299.
  60. Arlen AM, Leong T, Guidos PJ, et? al. Distal ureteral diameter ratio is predictive of breakthrough febrile urinary tract infection. J Urol. 2017;198:1418–1423.
  61. Arlen AM, Merriman LS, Kirsch JM, et ?al. Early effects of American Academy of Pediatrics urinary tract infection guidelines on radiographic imaging and diagnosis of vesicoureteral reflux in the emergency room setting. J Urol. 2015;193:1743–1759.
  62. Boysen WR, Ellison JS, Kim C, et? al. Multi-institutional review of outcomes and complications of robot-assisted laparoscopic extravesical ureteral reimplantation for treatment of primary vesicoureteral reflux in children. J Urol. 2017;197:1555–1561.
  63. Cannon GM, Ost MC. Robot-assisted laparoscopic extravesical ureteral reimplantation for vesicoureteral reflux. J Urol. 2017;197:1379–1381.
  64. Garcia-Roig M, Ridley DE, McCracken C, et ?al. Vesicoureteral reflux index: predicting primary vesicoureteral reflux resolution in children diagnosed after age 24 months. J Urol. 2017;197:1150–1157.
  65. Garcia-Roig M, Tavers C, McCracken CE, Kirsch AJ. National trends in the management of primary vesicoureteral reflux in children. J Urol. 2018;199:287–293.
  66. Gordon ZN, McLeod DJ, Becknell B, et? al. Uroepithelial thickening on sonography improves detection of vesicoureteral reflux in children with first febrile urinary tract infection. J Urol. 2015;194:1074–1079.
  67. Greenfield SP, Cheng E, DeFoor W, et? al. Vesicoureteral reflux and antibiotic prophylaxis: why cohorts and methodologies matter. J Urol. 2016;196:1238–1243.
  68. Grimsby GM, Dwyer ME, Jacobs MA, et? al. Multi-institutional review of outcomes of robot-assisted laparoscopic extravesical ureteral reimplantation. J Urol. 2015;193:1766–1771.
  69. Koyle MA, Butt H, Elder JS, et? al. Prolonged urinary retention can and does occur after any type of ureteral reimplantation. Pediatr Surg Int. 2017;33:623–626.
  70. Kurtz MP, Leow JJ, Varda BK, et? al. The decline of the open ureteral reimplant in the United States: national data from 2003 to 2013. Urology. 2017;100:193–197.
  71. Moriya K, Mitsui T, Kitta T, et? al. Early discontinuation of antibiotic prophylaxis in patients with persistent primary vesicoureteral reflux initially detected during infancy: outcome analysis and risk factors for febrile urinary tract infection. J Urol. 2015;193:637–642.
  72. Peters CA, Skoog SJ, Arant BS Jr, et? al. Summary of the AUA guideline on management of primary vesicoureteral reflux in children. J Urol. 2010;184:1134–1144.
  73. Ramsay S, Blais A-S, Morin F, et? al. Polyacrylamide hydrogel as a bulking agent for the endoscopic treatment of vesicoureteral reflux: long-term results and safety. J Urol. 2017;197:963–967.
  74. Rianthavorn P, Tangngamsakul O. Probabilities of dilating vesicoureteral reflux in children with first time simple febrile urinary tract infection, and normal renal and bladder ultrasound. J Urol. 2016;196:1541–1545.
  75. Shaikh N, Spingarn RB, Hum SW. The accuracy of two imaging tests in detecting vesicoureteral reflux. http://www.cochrane.org/CD010657/RENAL_accuracy-two-imaging-tests-detecting-vesicoureteral-reflux. July 5, 2016.
  76. Tewari R, Wang H-HS, Lloyd JC, et? al. Utility estimation for pediatric vescoureteral reflux: methodological considerations using online survey platform. J Urol. 2017;197: 805–810.
  77. Tran GN, Bodapati AV, Routh JC, et? al. Parental preference assessment for vesicoureteral reflux management in children. J Urol. 2017;197:957–962.
  78. Tullus K. Vesicoureteric reflux in children. Lancet. 2015;385:371–378.
  79. Wang HS, Gbadegesin RA, Foreman JW, et? al. Efficacy of antibiotic prophylaxis in children with vesicoureteral reflux: systematic review and meta-analysis. J Urol. 2015;193:963–969.
  80. Wang HS, Tejwani R, Wolf S, et ?al. Readmissions, unplanned emergency room visits, and surgical retreatment rates after anti-reflux procedures. J Pediatr Urol. 2017;13:507.e1–507.e7.
  81. Hidas G, Billimek J, Nam A, et? al. Predicting the risk of breakthrough urinary tract infections; primary vesicoureteral reflux. J Urol. 2015;194:1396–1401.
  82. Alyami FA, Koyle MA, Bowlin PR, et? al. Side-to-side refluxing nondismembered ureterocystotomy: a novel strategy to address obstructed megaureters in children. J Urol. 2017;198:1159–1167.
  83. Ansari MS, Singh P, Mandhani A, et? al. Delayed presentation in posterior urethral valve: long-term implications and outcome. J Urol. 2008;71:230–234.
  84. Braga LH, McGrath M, Farrokhyar F, et? al. Associations of initial Society for Fetal Urology grades and urinary tract dilatation risk groups with clinical outcomes in patients with isolated prenatal hydronephrosis. J Urol. 2017;197:831–837.
  85. Cundy TP, Harling L, Hughes-Hallett A, et ?al. Meta-analysis of robot-assisted vs conventional laparoscopic and open pyeloplasty in children. BJU Int. 2014;114:582–594.
  86. Elder JS. Antenatal hydronephrosis. In Puri P, editor: Newborn surgery, 4th ed, London: CRC Press; 2017, pp 1029–1047.
  87. Ellerkamp V, Kurth RR, Schmid E, et? al. Differences between intrinsic and extrinsic ureteropelvic junction obstruction related to crossing vessels: histology and functional analyses. World J Urol. 2016;34:577–583.
  88. Farrugia MK, Hitchcock R, Radford A, et? al. British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter. J Pediatr Urol. 2014;10:26–33.
  89. Garcia-Roig ML, Travers C, McCracken C, et? al. Surgical scar location preference for pediatric kidney and pelvic surgery: a crowdsourced survey. J Urol. 2017;197:911–919.
  90. Gatti JM, Anstutz SP, Bowlin PR, et? al. Laparoscopic vs open pyeloplasty in children: results of randomized, prospective, controlled trial. J Urol. 2017;197:792–797.
  91. Grimsby GM, Jacobs MA, Gargollo PC. Success of laparoscopic robot-assisted results of randomized, prospective, controlled trial. J Urol. 2017;197:792–797.
  92. Grimsby GM, Jacobs MA, Gargollo PC. Success of laparoscopic robot-assisted approaches to ureteropelvic junction obstruction based on preoperative renal function. J Endourol. 2015;29:874–877.
  93. Kapoor V, Elder JS. Simultaneous bilateral robotic-assisted laparoscopic procedures in children. J Robot Surg. 2015;9:285–290.
  94. Moscardi PRM, Barbosa JABA, Andrade HS, et? al. Reoperative laparoscopic uretero- pelvic junction obstruction obstruction repair in children: safety and efficacy of technique. J Urol. 2017;197:798–804.
  95. Murthy P, Cohn JA, Gundeti MS. Evaluation of robotic-assisted laparoscopic and open pyeloplasty in children: single-surgeon experience. Ann R Coll Surg Engl. 2015;97:109–114.
  96. Nguyen HT, Benson CB, Bromley B, et? al. Multidisciplinary consensus on the classifica- tion of prenatal and postnatal urinary tract dilation (UTD classification system). J Pediatr Urol. 2014;10:982–998.
  97. Oliveira EA, Oliveria MCL, Mak RH. Evaluation and management of hydronephrosis in the neonate. Curr Opin Pediatr. 2016;28:195–201.
  98. Paye-Jaouen A, Pistolesi F, Botto N, et? al. Long-term bladder function after ureterocele decompression in children. J Urol. 2015;193:1754–1759.
  99. Puri P, Shinkai M. Megacystis microcolon intestinal hypoperistalsis syndrome. Sem Pediatr Surg. 2005;14:58–63.
  100. Sander JC, Bilgutay AN, Stanasel I, et? al. Outcomes of endoscopic incision for the treatment of ureterocele in children at a single institution. J Urol. 2015;193:662–667.
  101. Scalabre A, Dem?de D, Gaillard S, et? al. Prognostic value of ultrasound grading systems in prenatally diagnosed unilateral urinary tract dilatation. J Urol. 2017;197:1144–1149.
  102. Scarborough PL, Ferrara E, Storm DW. Should prenatal hydronephrosis that resolves before birth be followed postnatally? Analysis and comparison to persistent prenatal hydronephrosis. Pediatr Nephrol. 2015;30:1485–1491.
  103. Silay MS, Undre S, Nambiar AK, et? al. Role of antibiotic prophylaxis in antenatal hydronephrosis: A systematic review from the European Association of Urology/ European Society for Paediatric Urology guidelines panel. J Pediatr Urol. 2017;13:306–315.
  104. Ziylan O, Oktar T, Ander H, et? al. The impact of late presentation of posterior urethral valves on bladder and renal function. J Urol. 2006;175:1894–1897.
  105. Ahmed H, Howe AS, Dyer LL, et? al. Robot-assisted laparoscopic urachal excision in children. Urology. 2017;106:103–106.
  106. Baumgartner TS, Lue KM, Sirisreetreerux P. et? al. Long-term sexual health outcomes in men with classic bladder exstrophy. BJU Int. 2017;120:422–427.
  107. Borer JG, Vasquez E, Canning DA, et? al. An initial report of a novel multi-institutional bladder exstrophy consortium: a collaboration focused on primary surgery and subsequent care. J Urol. 2015;193:1802–1807.
  108. Borer JG, Vasquez E, Canning DA, et ?al. Short-term outcomes of the multi-institutional bladder exstrophy consortium: successes and complications in the first two years of collaboration. J Pediatr Urol. 2017;13(275):e1–6.
  109. Celebi S, Sander S, Kuzdan O, et al. Current diagnosis and management of primary isolated bladder diverticula in children. J Pediatr Urol. 2015;11(61):e1–5.
  110. Ellison JS, Ahn J, Shnorhavorian M, et ?al. Long-term fate of the upper tracts following complete primary repair of bladder exstrophy. J Pediatr Urol. 2017;13(394):e1–6.
  111. Gleason JM, Bowlin PR, Bagli DJ, et? al. A comprehensive review of pediatric urachal anomalies and predictive analysis for adult urachal adenocarcinoma. J Urol. 2015;193:632–636.
  112. Ko J, Lue K, Friedlander D, et al. Cystectomy in the pediatric exstrophy population: indications and outcomes. Urology. 2018;116:168–171.
  113. Michaud JE, Ko JS, Lue K, et? al. Use of muscle pedicle flaps for failed bladder neck closure in the exstrophy spectrum. J Pediatr Urol. 2016;12(289):e1–e5.
  114. Sato H, Furuta S, Tsuji S, et? al. The current strategy for urachal remnants. Pediatr Surg Int. 2015;31:581–587.
  115. Stopak JK, Azarow KS, Abdessalam SF, et ?al. Trends in surgical management of urachal anomalies. J Pediatr Surg. 2015;50:1334–1337.
  116. Anselmo CB, do Amaral RD, Oliviera DE, et? al. Left-colon antegrade enema (LACE): long-term experience with the Macedo-Malone approach, Neurourol Urodyn 36:111–115, 2017.
  117. Bawa M, Dash V, Kalavant A, et ?al. Is urodynamic evaluation a must in all operated cases of open neural tube defects. J Pediatr Urol. 2017;13(6):614.e1–614.e4.
  118. Chaudhry R, Balsara ZR, Madden-Fuentes RJ, et? al. Risk factors associated with recur-rent urinary tract infection in neurogenic bladders managed by clean intermittent catheterization. Urology. 2017;102:213–218.
  119. Goldberg H, Aharov S, Levy Y, et? al. Low prevalence of latex allergy in children with spinal dysraphism in non-latex-free environment. J Pediatr Urol. 2016;12(1): 52.e1–52.e5.
  120. Grimsby GM, Burgess R, Culver S, et? al. Barriers to transition in young adults with neurogenic bladder. J Pediatr Urol. 2016;12:258.e1–258.e5.
  121. Grimsby GM, Jacobs MA, Gargollo PC. Comparison of complications of robot-assisted laparoscopic and open appendicovesicostomy in children. J Urol. 2015;194:772–776.
  122. Grimsby GM, Menon V, Schlomer BJ, et? al. Long-term outcomes of bladder neck recoonstruction without augmentation cystoplasty in children. J Urol. 2016;195:155–161.
  123. Hensle TW, Reiley EA, Fam MM, et ?al. Enterocystoplasty: the long-term effects on bone mineral density. J Pediatr Urol. 2016;12:245.e1–245.e6.
  124. Hidas G, Soltani T, Billimek J, et al. Home urodynamic pressures and volume measurement for the neurogenic bladder: initial validation study. J Urol. 2017;198:1424–1429.
  125. Husmann DA. Long-term complications following bladder augmentations in patients with spina bifida: bladder calculi, perforation of the augmented bladder and upper tract deterioration. Transl Androl Urol. 2016;5:3–11.
  126. Kaye IY, Payan M, Vemulakonda VM. Association between clean intermittent cath-eterization and urinary tract infection in infants and toddlers with spina bifida. J Pediatr Urol. 2016;12(5):284.e1–284.e6.
  127. Koyfman S, Swartz K, Goldstein AM, et al. Laparoscopic-assisted percutaneous endoscopic cecostomy (LAPEC) in children and young adults. J Gastrointest Surg. 2017;21:676–683.
  128. Leal da Cruz M, Liquori R, Garrone G, et ?al. A 4-year prospective urological assessment of in utero myelomeniingocele repair–does gestational age at birth have a role in later neurogenic bladder pattern? J Urol. 2017;197:1550–1554.
  129. Liu T, Ouyang L, Thibadeau J, et?al: Longitudinal study of bladder continence among people with spina bifida in the national spina bifida patient registry. J Urol. 2018;199(3):837–843.
  130. Polm PD, de Kort LMO, de Jong TPMV, et al. Techniques used to create continent catheterizable channels: a comparison of long-term results in children. Urology. 2017;110:192–195.
  131. Routh JC, Cheng EC, Austin JC, et ?al. Design and methodological considerations of the centers for disease control and prevention urologic and renal protocol for the newborn and young child with spina bifida. J Urol. 2016;196:1728–1734.
  132. Rove KO, Husmann DA, Wilcox DT, et? al. Systematic review of bladder cancer outcomes in patients with spina bifida. J Pediatr Urol. 2017;13(5):456.e1–456.e9.
  133. Sager C, Burek C, Corbetta JC, et? al. Initial urological evaluation and management of children with neurogenic bladder dur to myelomeningocele. J Pediatr Urol. 2017;13(3):271.e1–271.e5.
  134. Shepard CL, Yan PL, Hollingsworth JM, et ?al. Pregnancy among mothers with spina bifida. J Pediatr Urol. 2018;14(1):11.e1–11.e6.
  135. Snow-Lisy DC, Yerkes EB, Cheng EY. Update on urological management of spina from prenatal diagnosis to adulthood. J Urol. 2015;194:288–296.
  136. Toh S, Boswell-Ruys CL, Lee BB, et ?al. Probiotics for preventing urinary tract infections in people with bladder dysfunction after a nervous system injury, https://www.cochrane.org/CD010723/RENAL_probiotics-preventing-urinary-tract-infections-people-bladder-dysfunction-after-nervous-system, September 8, 2017.
  137. Wang HH, Lloyd JC, Wiener JS, Routh JC. Nationwide trends and variations in urological surgical interventions and renal outcome in patients with spina bifida. J Urol. 2016;195:1189–1194.
  138. Wang HH, Wiener JS, Ross SS, et al. Emergent care patterns in patients with spina bifida: a case-control study. J Urol. 2015;193:268–273.
  139. Blais AS, Bergeron M, Nadeau G, et ?al. Anticholinergic use in children: persistence and patterns of therapy. Can Urol Assoc J. 2016;10:137–140.
  140. Blais AS, Nadeau G, Moore K, et? al. Prospective pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol. 2016;70:9–13.
  141. Borg B, Kamperis K, Olsen LH, et? al. Evidence of reduced bladder capacity at night in children with monosymptomatic nocturnal enuresis. J Pediatr Urol. 2018;14(2):160.e1–160.e6.
  142. Braga LH, Rickard M, Farrokhyar F, et? al. Bladder training video versus standard urotherapy for bladder and bowel dysfunction: a noninferiority randomized, controlled trial. J Urol. 2017;197:877–884.
  143. Caldwell PHY, Sureshkumar P, Wong WCF. Tricyclics and related drugs for treating bedwetting in children. http://www.cochrane.org/CD002117/INCONT_tricyclics -and-related-drugs-treating-bedwetting-children. (ïî ñîñòîÿíèþ íà 20 ÿíâàðÿ 2016 ã.).
  144. Fazeli MS, Lin Y, Nikoo N, et? al. Biofeedback for nonneuropathic daytime voiding disorders in children: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2015;193:274–280.
  145. Franco I, Arlen AM, Collett-Gradere T, et? al. Imipramine for refractory daytime incontinence in the pediatric population. J Pediatr Urol. 2018;14(1):58.e1–58.e5.
  146. Hara T, Ohtomo Y, Endo A, et? al. Evaluation of urinary aquaporin 2 and plasma copeptin as biomarkers of effectiveness of desmopressin acetate for the treatment of monosymptomatic nocturnal enuresis. J Urol. 2017;198:921–927.
  147. Jorgensen CS, Kamperis K, Borch L, et al. Transcutaneous electrical nerve stimulation in children with monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo controlled study. J Urol. 2017;198:687–693.
  148. Logan BL, Blais S: Giggle incontinence: evolution of concept and treatment. J Pediatr Urol. 2017;13:430–435.
  149. Morin F, Blais A-S, Nadeau G, et al. Dual therapy for refractory overactive bladder in kids: prospective open study. J Urol. 2017;197:1158–1163.
  150. Nevo A, Mano R, Livne PM, et? al. Urinary retention in children. Urology. 2014;84:1475–1479.
  151. Newgreen D, Bosman B, Hollestein-Have-laar A, et ?al. Long-term safety and safety of solifenacin in children and adolescents with overactive bladder. J Urol. 2017;198:928–938.
  152. Onol FF, Guzel R, Tahra A, et? al. Comparison of long-term efficacy of desmopressin lyophilisate and enuretic alarm for monosymptomatic enuresis and assessment of predictive factors for success: a randomized prospective trial. J Urol. 2015;193:655–661.
  153. Patidar N, Mittal V, Kumar M, et al. Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder: a preliminary report. J Pediatr Urol. 2015;351.e1–351.e6.
  154. Samjin B, Van end Broeck C, Deschepper E, et?al: Risk factors for daytime or combined incontinence in children with cerebral palsy, J Urol 198:937–943, 2017.
  155. Schober MS, Sulkowski JP, Lu PL, et? al. Sacral nerve stimulation for pediatric lower urinary tract dysfunction: development of a standardized pathway with objective urodynamic outcomes. J Urol. 2015;194:1721–1726.
  156. Sulkowski JP, Nacion KM, Deans KJ, et? al. Sacral nerve stimulation: a promising therapy for fecal and urinary incontinence and constipation in children. J Pediatr Surg. 2015:50:1644–1647.
  157. Zhao PT, Velez D, Faiena I, et? al. Bullying has a potential role in pediatric lower urinary tract symptoms. J Urol. 2015;193:1743–1748.
  158. Asgari SA, Safarinejad MR, Poorreza F, et? al. The effect of parenteral testosterone administration prior to hypospadias surgery: a prospective, randomized and controlled study. J Pediatr Urol. 2015;11:143.e1–143.e6.
  159. Babu R, Chakravarthi C. The role of preoperative intramuscular testosterone in improving functional and cosmetic outcomes following hypospadias repair: a prospective randomized study. J Pediatr Urol. 2018;14(1):29.e1–29.e6.
  160. Bonitz RP, Hanna MK. Correction of congenital penoscrotal webbing in chil-dren: a retrospective review of three surgical techniques. J Pediatr Urol. 2016;12:161.e1–161.e5.
  161. Braga LS, Jegatheeswaran K, McGrath M, et? al. Cause and effect versus confounding—is there a true association between caudal blocks and tubularized incised plate repair complications? J Urol. 2017;197:845–851.
  162. Campbell J, Gillis J. A review of penile elongation surgery. Transl Androl Urol. 2017;6:69–78.
  163. Cimador M, Catalano P, Ortolano R, et? al. The inconspicuous penis in children. Nat Rev Urol. 2015;12:205–215.
  164. Concodora CW, Maizels M, Elder JS, et? al. Checklist assessment tool to evaluate suitability and success of neonatal clamp circumcision: a prospective study. J Pediatr Urol. 2016;12(4):235.e1–235.e5.
  165. Haid B, Becker M, Koen C, et al. Penile appearance after hypospadias correction from a parent’s point of view: comparison of the hypospadias objective penile evaluation score and parents penile perception score. J Pediatr Urol. 2016;12:33.e1–33.e7.
  166. Liao AY, Smith GH. Urethrocutaneous fistulae after hypospadias repair: when do they occur? J Paediatr Child Health. 2016;52:556–560.
  167. Long CJ, Chu DI, Tenney RW, et? al. Intermediate-term follow-up of proximal hypo-spadias repair reveals high complication rate. J Urol. 2017:852–858.
  168. McNamara ER, Schaeffer AJ, Logvinenko T, et al. Management of proximal hypospadias with 2-stage repair: 20-year experience. J Urol. 2015;194:1080–1085.
  169. Menon P, Rao KLN, Handu A, et? al. Outcome of urethroplasty after parenteral testosterone in children with distal hypospadias. J Pediatr Urol. 2017;13:292.e1–292.e7.
  170. Moreno G, Corbal?n J, Pe?aloza B, Pantoja T. Topical corticosteroids for treating phimosis in males, 2014. http://www.cochrane.org/CD008973/RENAL_topical -corticosteroids-for-treating-phimosis-in-males.
  171. Seleim HM, Elbarbary MM. Major penile injuries as a result of cautery during newborn circumcision. J Pediatr Surg. 2016;51:1532–1537.
  172. Sneppen I, Thorup J. Foreskin morbidity in uncircumcised males. Pediatrics. 2016;137(5):e20154340.
  173. Stoupa A, Samara-Boustana D, Flechtner I, et? al. Efficacy and safety of continuous subcutaneous infusion of recombinant human gonadotropins for congenital micropenis during early infancy. Horm Res Paediatr. 2017;87:103–110.
  174. Zheng Z, Armfield BA, Cohn MJ. Timing of androgen receptor disruption and estrogen exposure underlies a spectrum of congenital penile anomalies. Proc Natl Acad Sci USA. 2015;112:E7194–E7203.
  175. Bayne CE, Villanueva J, Davis TD, et al. Factors associated with delayed presentation and misdiagnosis of testicular torsion: a case-control study. J Pediatr. 2017;186:200–204.
  176. Cayan S, Sahin S, Akbay E. Paternity rates and time to conception in adolescents with varicocele undergoing microsurgical varicocele repair vs observation only: a single institution experience with 408 patients. J Urol. 2017;198:195–201.
  177. Christman MS, Zderic SA, Canning DA, et al. Active surveillance of the adolescent with varicocele: predicting semen outcomes from ultrasound. J Urol. 2014;191:1401–1406.
  178. Dayanir YO, Akdilli A, Karaman CZ, et? al. Epididymoorchitis mimicking testicular torsion in Henoch-Sch?nlein purpura. Eur Radiol. 2001;11:2267–2269.
  179. Dias Fiho AC, Rodrigues RO, Riccetti CLZ, et? al. Improving organ salvage in testicular torsion: comparative study of patients undergoing vs not undergoing preoperative manual detorsion. J Urol. 2017;197:811–817.
  180. Elder JS. Surgical management of the undescended testis: recent advances and controversies. Eur J Pediatr Surg. 2016;26:418–426.
  181. Fine RG, Gitlin J, Reda EF, et?al. Barriers to use of semen analysis in the adolescent with a varicocele: survey of patient, parental, and practitioner attitudes. J Pediatr Urol. 2016;12:41.e1–41.e6.
  182. Garcia-Roig ML, Kirsch AJ. The dilemma of adolescent varicocele. Pediatr Surg Int. 2015;31:617–625.
  183. Gurney JK, McGlynn KA, Stanley J, et? al. Risk factors for cryptorchidism. Nat Rev Urol. 2017;14:534–548.
  184. Holland AJA, Nassar N, Schneuer FJ. Undescended testes: an update. Curr Opin Pediatr. 2016;28:388–394.
  185. Hutson JM, Thorup J. Evaluation and management of the infant with cryptorchidism. Curr Opin Pediatr. 2015;27:520–524.
  186. Jensen CFS, Ostergren P, Dupree JM, et ?al. Varicocele and male infertility. Nat Rev Urol. 2017;14:523–533.
  187. Kalisvaart JF, Broecker B, Cerwinka WH, et al. Pediatric chronic orchalgia. J Pediatr Urol. 2012;8:421–425.
  188. Kurtz MP, Zurakowski D, Rosoklija I, et? al. Semen parameters in adolescents with varicocele: association with testis volume differential and total testis volume. J Urol. 2015;193:1843–1847.
  189. Locke JA, Noparast M, Afshar K. Treatment of varicocele in children and adolescents: a systematic review and meta-analysis of randomized controlled trials. J Pediatr Urol. 2017;13(5):437–445.
  190. Pastuszak W, Kumar V, Shah A, et al. Diagnostic and management approaches to pediatric and adolescent varicocele: a survey of pediatric urologists. Urology. 2014;84:450–455.
  191. Peycelon M, Rossignol G, Muller CO, et? al. Testicular prostheses in children: is earlier better? J Pediatr Urol. 2016;12:237.e1–237.e6.
  192. Samson P, Hartman C, Palmerola R, et? al. Ultrasonographic assessment of testicular viability using heterogeneity levels in torsed testicles. J Urol. 2017;197:925–930.
  193. Schneuer FJ, Holland AJA, Pereira G, et? al. Age at surgery and outcomes of an undescended testis. Pediatrics. 2016;137(2):e20152768.
  194. Sood A, Li H, Suson KD, Elder JS. Treatment patterns, testicular loss and disparities in inpatient surgical management of testicular torsion in males: a population-based study 1998-2010. BJU Int. 2016;118:969–979.
  195. Meulen BC, Peters EW, Wijsmuller A, et? al. Acute scrotal pain from idiopathic ilioinguinal neuropathy: diagnosis and treatment with EMG-guided nerve block. Clin Neurol Neurosurg. 2017;109:535–537.
  196. Thorup J, Clasen-Linde E, Thorup SC, et? al. Pre- and postoperative status of gonado-tropins (FSH and LH) and inhibin-b in relation to testicular histopathology at orchiopexy in infant males with unilateral undescended testes. J Pediatr Urol. 2015;11:25.e1–25.e5.
  197. Xu C, Liu M, Zhang FF, et? al. The association between testicular microlithiasis and semen parameters in Chinese adult men with fertility intention: experience of 226 cases. Urology. 2014;84:815–820.
  198. Amerstorfer EE, Haberlik A, Riccabona M. Imaging assessment of renal injuries in children and adolescents: CT or ultrasound? J Pediatr Surg. 2015;50:448–455.
  199. Au JK, Tan X, Sidani M, et ?al. Imaging characteristics associated with failure of nonoperative management in high-grade pediatric blunt renal trauma. J Pediatr Urol. 2016;12:294.e1–294.e6.
  200. Bieniek JM, Sumfest JM. Sports-related testicular injuries and the use of protective equipment among young male athletes. Urology. 2014;84:1485–1489.
  201. Delaney KM, Reddy SH, Dayama A, et? al. Risk factors associated with bladder and urethral injuries in female children with pelvic fractures: an analysis of the national trauma data bank. J Trauma Acute Care Surg. 2016;80:472–476.
  202. Fenton LZ, Karakas SP, Baskin L, et al. Sonography of pediatric blunt scrotal trauma: what the pediatric urologist wants to know. Pediatr Radiol. 2016;46:1049–1058.
  203. Fuchs ME, Anderson RE, Myers JB, et ?al. The incidence of long-term hypertension in children after high-grade renal trauma. J Pediatr Surg. 2015;50:1919–1921.
  204. Kurtz MP, Eswara JR, Vetter JM, et? al. Blunt abdominal trauma from motor vehicle collisions from 2007 to 2011: renal injury probability and severity in children versus adults. J Urol. 2017;197:906–910.
  205. Lee JN, Lim JK, Woo MJ, et al. Predictive factors for conservative treatment failure in grade IV pediatric blunt renal trauma. J Pediatr Urol. 2016:93.e1–93.e7.
  206. LeeVan E, Zmora O, Cazzulino F, et al. Management of pediatric blunt renal trauma: a systematic review. J Trauma Acute Care Surg. 2016;80:519–528.
  207. Meltzer JA, Reddy SH, Blumfield E, et? al. Pelvic fracture urethral injuries in children: a case report and appraisal of their emergency management. Pediatr Emerg Care. 2016;32:627–629.
  208. Papagiannopoulos D, Gong E. Revisiting sports precautions in children with solitary kidneys and congenital anomalies of the kidney and urinary tract. Urology. 2017;101:9–14.
  209. Podesta M, Podesta M Jr. Delayed surgical repair of posttraumatic posterior urethral distraction defects in children and adolescents: long-term results. J Pediatr Urol. 2015;11(2):67.e1–67.e6.
  210. Roland D, Lewis G, Rowlands R, et? al. Female perineal injuries in children and adoles-cents presenting to a paediatric emergency department. Emerg Med J. 2016;33:73–75.
  211. Terrier JE, Paparel P, Gadegbeku B, et ?al. Genitourinary injuries after traffic accidents: analysis of a registry of 162,690 victims. J Trauma Acute Care Surg. 2017;82:1087–1093.
  212. Trachta J, Moravek J, Kriz J, et al. Pediatric bulbar and posterior urethral injuries: operative outcomes and long-term follow-up. Eur J Pediatr Surg. 2016;26:86–90.
  213. Wolf MF, George RP, Warshaw B, et? al. Physical activity and kidney injury in pediatric and young adult kidney transplant recipients. J Pediatr. 2016;179:90–95.e2.
  214. Aldaqadissu HA, Salem HK, Koth Y, et? al. Prediction of pediatric percutaneous nephro-lithotomy outcomes using contemporary scoring systems. J Urol. 2017;198:1146–1152.
  215. Bujons A, Mill?n F, Centeno C, et? al. Mini-percutaneous nephrolithotomy with high-power holmium YAG laser in pediatric patients with staghorn and complex calculi. J Pediatr Urol. 2016;12:253.e1–253.e5.
  216. Dangle P, Ayyash O 4th, Shaikh H 3rd, et al. Predicting spontaneous stone passage in prepubertal children: a single institution cohort. J Endourol. 2016;30:945–949.
  217. Ellison JS, Kaufman SR, Kraft KH, et al. Underuse of 24-hour urine collection among children with incident urinary stones: a quality-of-care concern? Urology. 2014;84:457–461.
  218. Freton L, Peyronnet B, Arnaud A, et? al. Extracorporeal shockwave lithotripsy versus flexible ureteroscopy for the management of upper tract urinary stones in children. J Endourol. 2017;31:1–6.
  219. Gross IT, Ford R. Emphysematous pyelonephritis in a child with nephrolithiasis. J Pediatr. 2016;168:250.
  220. Hollingsworth JM, Canales BK, Rogers MAM, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016;355:i6112.
  221. Hsi RS, Sanford T, Goldfarb DS, et? al. The role of the 24-hour urine collection in the prevention of kidney stone recurrence. J Urol. 2017;197:1084–1089.
  222. Mello MF, Marchini GS, C?mara C, et? al. A large 15-year database analysis on the influence of age, gender, race, obesity and income on hospitalization rates due to stone disease. Int Braz J Urol. 2016;42:1150–1159.
  223. Morrison JC, Van Batavia JP, Darge K, et al. Ultrasound guided ureteroscopy in children: safety and success. J Pediatr Urol. 2018;114(1):64.e1–64.e6.
  224. Mulay SP, Anders HJ. Crystallopathies. N Eng J Med. 2016;374(25):2465–2476.
  225. Pathan SA, Mitra B, Cameron PA. A systematic review and meta-analysis comparing the efficacy of nonsteroidal anti-inflammatory drugs, opioids, and paracetamol in the treatment of acute renal colic. Eur Urol. 2018;73(4):583–595.
  226. Smith-Bindman R, Aubin C, Bailitz J, et ?al. Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med. 2014;371(12):1100–1110
  227. Swearingen R, Sood A, Elder JS, et? al. Zero-fragment nephrolithotomy: a multi-center evaluation of robotic pyelolithotomy and nephrolithotomy for treating renal stones. Eur Urol. 2017;72(6):1014–1021.
  228. Tasian GE, Kabarriti AE, Kalmus A, et? al. Kidney stone recurrence among children and adolescents. J Urol. 2017;197:246–252.
  229. Tian D, Li N, Huang W, et ?al. The efficacy and safety of adrenergic alpha-antagonists in treatment of distal ureteral stones in pediatric patients: A systematic review and meta-analysis. J Pediatr Surg. 2017;52:360–365.
  230. Van Batavia JP. Tasian GE: clinical effectiveness in the diagnosis and acute management of pediatric nephrolithiasis. Int J Surg. 2016;36:698–704.
  231. Wang HH, Wiener JS, Lipkin ME, et? al. Estimating the nationwide, hospital based economic impact of pediatric urolithiasis. J Urol. 2015;193:1855–1859.
  232. Yadav SS, Aggarwal SP, Mathur R, et? al. Pediatric percutaneous nephrolithotomy-experience of a tertiary care center. J Endourol. 2017;31:246–254.
  233. Ziemba JB, Canning DA, Lavelle J, et? al. Patient and institutional characteristics associated with initial computerized tomography in children presenting to the emergency department with kidney stones. J Urol. 2015;193:1848–1854.

Òðóäû îòå÷åñòâåííûõ àâòîðîâ ïðè ïîäãîòîâêå ñòàòåé ïî ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà - íå èñïîëüçîâàëèñü, òàê êàê èõ âû âñåãäà ìîæåòå íàéòè â áèáëèîòåêàõ.

- Âåðíóòüñÿ â ðàçäåë "Ïåäèàòðèÿ"

Ðåäàêòîð: Èñêàíäåð Ìèëåâñêè. Äàòà îáíîâëåíèÿ ïóáëèêàöèè: 22.6.2024

Ìåäóíèâåð Ìû â Telegram Ìû â YouTube Ìû â VK Ôîðóì êîíñóëüòàöèé âðà÷åé Êîíòàêòû, ðåêëàìà
Èíôîðìàöèÿ íà ñàéòå ïîäëåæèò êîíñóëüòàöèè ëå÷àùèì âðà÷îì è íå çàìåíÿåò î÷íîé êîíñóëüòàöèè ñ íèì.
Ñì. ïîäðîáíåå â ïîëüçîâàòåëüñêîì ñîãëàøåíèè.